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  INTRODUCTION 
2. Introduction 
In the United States and Europe cardiovascular disease, including stroke is the major cause of 
death and morbidity. The common pathological substrate forming the basis of coronary heart 
disease and ischemic stroke is dysfunction of the endothelium leading to atherosclerosis. 
Atherosclerotic narrowed or blocked arteries impair blood flow and cause tissue ischemia. 
Manifest ischemic stroke and myocardial infarction usually originate from rupture of 
atherosclerotic plaques and consequent thrombotic occlusion of arteries. The molecular 
mechanisms underlying myocardial infarction, stroke and atherosclerosis are very complex and 
a large variety of molecules and signaling processes is needed to promote the inflammatory 
response and wound healing (Ross, 1999; Davignon & Ganz, 2004; Hansson, 2005; 
Frangogiannis et al., 2002; Zheng & Yenari, 2004). Another major issue in ischemic tissues is 
neovascularization. Sprouting of new vessels is observed after infarction of the brain and the 
heart as is the formation of collaterals in chronic ischemia. Since common therapeutic strategies 
to restore blood flow in tissue affected by ischemia such as implantation of bypass grafts or 
angioplasty/stenting have their mechanical limitations, new therapeutic approaches to rescue 
ischemic tissue by inducing vessel growth to ameliorate angina symptoms and reduce loss of 
functional tissue have attracted much attention. To apply a specific therapy, molecular 
mechanisms of neovascularization involving a large variety of factors and signaling pathways 
need to be closely understood (Greenberg & Jin, 2005; Krupinski et al., 1994; Nelissen-
Vrancken et al., 1996; Toyota et al., 2004; Schaper & Ito, 1996). 
2.1.  Angiogenesis, arteriogenesis and vasculogenesis 
Blood vessel growth, generally referred to as neovascularization, is distinguished in three 
different processes that participate in the formation of the vascular system (Simons, 2005).  
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(1) Angiogenesis is mainly characterized as sprouting of new vessels out of pre-existing 
capillaries. One of the most important stimuli for angiogenesis is hypoxia, which strongly 
regulates angiogenesis via hypoxia inducible factor 1-α (HIF-1α) (Simons, 2005; Carmeliet, 
2003).  
(2) Arteriogenesis is triggered by local alterations in shear-stress in the vicinity of arterial 
occlusion, but mainly occurs outside areas of ischemia. It is currently debated whether 
arteriogenesis describes a process of de novo forming collaterals that are stabilized by mural 
cells such as smooth muscle cells or the remodeling of pre-existing arterioles into larger 
conductance arteries (Simons 2005; Carmeliet 2000; Carmeliet, 2003; Schaper & Scholz, 
2003).  
(3) Vasculogenesis occurs during embryogenesis and describes a process of local formation of a 
primitive vascular network by differentiation of immature endothelial progenitor cells 
(angioblasts) into endothelial cells that form a primitive vascular network. Lately, it could be 
shown that endothelial progenitor cells (EPCs) derived from the bone marrow also circulate 
postnatally in the peripheral blood and contribute to postnatal neovascularization (postnatal 
vasculogenesis) (Carmeliet, 2000; Luttun & Carmeliet, 2003; Asahara et al., 1999). 
 
2.2. Angiogenesis and vasculogenesis in ischemic cardiovascular disease 
Angiogenesis can be found in the infarcted area after myocardial infarction and stroke.  
In ischemic stroke angiogenesis is observed in the penumbra, the border zone of the infarcted 
area. In contrast to the core of the infarcted area, blood supply in the penumbra is diminished 
but not absent. Improvement of blood flow in the penumbra might have an impact on cell 
survival and limitation of tissue damage. It could be shown that vascular endothelial growth 
factor (VEGF)-induced angiogenesis after stroke in rats was beneficial regarding the 
 6
  INTRODUCTION 
neurological deficit (Krupinski et al., 1994; Greenberg & Jin, 2005; Zhang et al., 2000). Similar 
to ischemic stroke, angiogenesis is also found in the border zone of myocardial infarction. In 
the acute phase of infarction, pre-existing collateral vessels limit the infarct size and increase 
the blood flow to the injured area. The chronic phase is characterized by the appearance of 
newly formed vessels in the area of infarction that are a critical step to the final restoration of 
blood flow (Nelissen-Vrancken et al., 1996; Cleutjens et al., 1999). 
Therapeutic administration of pro-angiogenic factors such as VEGF and fibroblast growth 
factor (FGF) to induce vessel growth by angiogenesis has been given much thought lately 
(Simons & Ware, 2003; Toyota et al., 2004). Apart from that, postnatal vasculogenesis is 
another major issue in the therapeutic attempt to rescue ischemic tissue. In embryonic 
vasculogenesis, EPCs are assembled to form a primitive vascular network. Postnatally, EPCs 
are also found to circulate in the peripheral blood and have the ability to proliferate and 
differentiate into mature endothelial cells. It has been shown that EPCs may contribute to 
neovascularization in ischemic tissue consistent with postnatal vasculogenesis (Asahara et al., 
1997; Takahashi et al., 1999; Asahara et al., 1999; Hristov et al., 2003; Dzau et al., 2005).  
Embryonic endothelial progenitor cells (eEPCs) were first isolated by Hatzopoulos et al., 
(1998) from murine embryos at E7.5. These cells appear in early embryonic vascular 
development and show the characteristic properties of endothelial progenitors as well as 
unlimited stem-cell like growth. In vitro, eEPCs retain their progenitor properties and have the 
potential to differentiate under the influence of retinoic acid and cyclic adenosine 
monophosphate (cAMP) showing a more typical gene expression profile and morphology for 
endothelial cells. It has been shown, that eEPCs contribute to neovascularization in tumors and 
preferentially home to hypoxic metastases (Vajkoczy et al., 2003; Wei et al., 2004). Recent 
studies show that eEPCs increase neovascularization and improve tissue recovery in a model of 
chronic hind limb ischemia in rabbits as well as in a model of myocardial ischemia in mice. It 
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should be noted that administration of eEPCs to sites of ischemia seems to induce angiogenesis, 
possibly through a broad range of eEPC-secreted factors (Kupatt et al., 2005). Therefore, 
eEPCs are a powerful model to study regulation of vascular development and factors involved 
in the formation of vessels. 
 
2.3. Regulation of angiogenesis and vasculogenesis by hypoxia and the role of 
VEGF 
Among other metabolic conditions that promote angiogenesis, such as acidosis and 
hypoglycaemia, hypoxia is an important stimulus for angiogenesis (Emanueli & Madeddu, 
2001). It has been hypothesized that alterations in oxygen availability in tissues is sensed by the 
HIF hydroxylase system. Low oxygen availability leads to the activation of HIF-1α, a 
transcription factor that is known to act as a key regulator of oxygen homeostasis at the 
transcriptional level (together with HIF-1ß). Most importantly among the genes induced by 
HIF-1α is VEGF, which is thus regulated by hypoxia (Pugh & Ratcliffe, 2003; Strieter, 2005).  
VEGF is one of the most important growth factors in angiogenesis. Six members belong to the 
VEGF gene family: VEGF-A – VEGF-E and placental growth factor (PLGF). VEGF-A 
(usually referred to as VEGF) has been shown to be involved, beside other factors, in several of 
the steps leading to the formation of new vessels. VEGF for example increases vascular 
permeability and promotes endothelial cell growth as well as endothelial cell survival (Ferrara 
et al., 2003; Carmeliet, 2000).  
Besides angiogenesis, hypoxia also seems to be a stimulus for postnatal vasculogenesis. It could 
be shown that the number of postnatal circulating EPCs was augmented in animal models of 
tissue ischemia which was accompanied by increased neovascularization (Takahashi et al., 
1999).  
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2.4. Canonical Wnt signaling and inhibition of Wnt signaling by Dkk-1 
Wnt signaling is well established in development and disease, especially cancer (Cadigan & 
Nusse, 1997; Polakis, 2000). However, an additional role of Wnt signaling in cardiovascular 
disease has only recently begun to take shape. Components of the Wnt signaling pathway have 
been found to be involved in wound healing after myocardial infarction and neovascularization 
processes (van Gijn et al., 2002). Interestingly, several genes that are known to participate in 
angiogenesis have been shown to be Wnt target genes. An increasing body of evidence leads to 
the suggestion, that Wnt signaling is one of the pathways involved in the formation and 
remodeling of blood vessels (Goodwin & D´Amore, 2002). 
Wnt signaling is initiated by binding of Wnt proteins to frizzled (Fz) receptors located in the 
cell membrane (Bhanot et al., 1996). Wnt proteins are a family of secreted glycoproteins, which 
represent a major group of developmental regulators (Cadigan & Nusse, 1997; Logan & Nusse, 
2004). In mammals, 19 different Wnt homologs and 10 different Fz receptors have been 
identified (for updates on Wnt signaling see: http: 
//www.stanford.edu/~rnusse/wntwindow.html). Different Wnt proteins seem to preferably 
activate distinct pathways, i.e., the Wnt/ß-catenin pathway or the Wnt/Ca2+ pathway that are 
involved in lineage specification and body axis formation in early embryos (Kühl et al., 2000; 
Miller et al., 1999; Wharton, 2003). The third pathway is the Planar Cell Polarity/Convergent 
Extension pathway (PCP/CE), which mainly promotes tissue polarity and convergent extension 
movements. Disheveled (Dvl), a protein downstream from the Fz receptors is supposed to be 
the node between Wnt/ß-catenin and PCP signaling and seems to be able to discriminate among 
the different pathways by distinct interactions of its protein domains (Boutros et al., 1998; 
Wharton, 2003; Povelones & Nusse, 2002). The Wnt/ß-catenin signaling pathway is referred to 
as the canonical Wnt pathway, whereas Wnt/Ca2+ and PCP signaling pathways are termed 
noncanonical Wnt signaling pathways (Fig.1).  
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Figure 1 The Wnt protein activates three different pathways. By binding to Fz receptors, either the Wnt/Ca2+ 
pathway (left) that promotes tissue separation and ventral axis identity is activated or signals are transmitted 
through Dvl. Dvl is thought to be able to distinguish signals and promote signaling through the planar cell polarity/ 
convergent extension pathway or the Wnt/ß-catenin pathway that leads to ß-catenin accumulation and transcription 
of target genes. LRP is believed to function specifically in Wnt/ß-catenin signaling.  
 
In cardiovascular disease, however, most insight has been gained on components and targets of 
the canonical Wnt pathway. There also might be a role for noncanonical Wnt signaling 
pathways in cardiovascular disease and in the vasculature, but this has not been closely 
investigated (Goodwin & D´Amore, 2002). Further focus of this work will therefore be on the 
canonical Wnt signaling pathway.  
Canonical Wnt signaling is thought to be activated by binding of Wnt proteins to Fz receptors 
in the presence of the co-receptor low density lipoprotein (LDL) receptor-related protein 6 
(LRP6) and apparently also LRP5, which shares 71% amino-acid identity with LRP6 (Tamai et 
al., 2000; Wehrli et al., 2000; Pinson et al., 2000; Mao et al., 2001). The exact nature of 
activation of Wnt signaling and transduction of the signal to the cell has only been poorly 
understood and is currently controversial discussed. It has been proposed that the formation of a 
ternary complex consisting of the Wnt protein, the Fz receptor and the co-receptor LRP 5/6 and 
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the association of this complex with intracellular Axin is necessary for transduction of the 
signal (Tamai et al., 2004; Mao et al., 2001; Tolwinski & Wieschaus, 2004). In this process Dvl 
seems to be required in relocating Axin to the plasma membrane (Cliffe et al., 2003).  
Active Wnt signaling leads to the release of ß-catenin from a cytosolic complex, consisting 
mainly of the scaffolding protein Axin, the tumor suppressor protein adenomatous polyposis 
coli (APC), the glycogen synthetase kinase-3ß (GSK-3ß), the casein kinase I (CKI) and ß-
catenin. In the absence of Wnt signaling, ß-catenin is phosphorylated by GSK-3ß and CKI 
which results in the degradation of ß-catenin. Positive Wnt signaling blocks phosphorylation of 
ß-catenin, which is subsequently not degraded. This process leads to accumulation and 
stabilization of cytosolic ß-catenin, which is now able to translocate to the nucleus. The 
presence of ß-catenin in the nucleus and its interactions with the T-cell-specific transcription 
factor (Tcf)/ lymphoid enhancer-binding factor (Lef) DNA-binding proteins mediate the 
transcription of Wnt-signaling-depending target genes (Logan & Nusse, 2004; Polakis, 2002; 
Clevers & van de Wetering, 1997; Behrens et al, 1996; Molenaar et al., 1996).  
Wnt signaling is regulated by a number of extracellular inhibitors. Among the many factors that 
inhibit Wnt signaling are the secreted frizzled related proteins (sFRPs), Wnt inhibitory factor 
(WIF) and the Dickkopf (Dkk) gene family, that comprises three members in mice (Dkk-1, Dkk-
2 and Dkk-3) and four members in humans (DKK-1, DKK-2, DKK-3 and DKK-4). It should be 
noted, however, that distinct Wnt proteins that preferably activate noncanonical Wnt signaling 
are also able to inhibit canonical Wnt signaling (Kawano & Krypta, 2003) (Fig.2).  
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Figure 2 Simplified schematic drawing of the canonical Wnt signaling pathway. Wnt signaling is 
initiated by binding of the Wnt protein to the Fz receptor and the co-receptor LRP5/6. The signal is passed via Dvl 
and the cytosolic complex consisting of Axin, APC, CK I, GSK-3ß and ß-catenin. In the case of active signaling 
phosphorylation of ß-catenin by CK I and GSK-3ß is inhibited which leads to a release of ß-catenin from the 
complex. ß-catenin accumulates in the cytoplasm and translocates to the nucleus where it interacts with 
transcription factors (Tcf/Lef family) thus promoting the transcription of target genes. Apart from its role in Wnt 
signaling ß-catenin plays also a role in cell adhesion. ß-catenin links cadherins in the cell membrane, for example 
VE-cadherin in endothelial cells, to the actin cytoskeleton. 
Wnt signaling is inhibited by different extracellular antagonists (Dkk, sFRP, WIF) that interfere directly or  
indirectly with the Wnt protein. In the absence of Wnt signaling ß-catenin is phosphorylated by GSK-3ß or 
CKI and subsequently degraded. 
 
One of the best characterized Wnt inhibitors is Dkk-1. Dkk-1, the first member of the Dkk gene 
family, was described in 1998. It was shown to be a potent Wnt antagonist and is required for 
head formation in Xenopus laevis and mice (Glinka et al., 1998; Mukhopadhyay et al., 2001).  
Dkk-1 inhibits Wnt signaling by directly interacting with LRP6. It has been shown, that LRP6 
is a high-affinity receptor for Dkk-1 and Dkk-2, independent of Fz. It is thought that Dkk-1 
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blocks Wnt/ß-catenin signaling by disrupting the Fz-LRP6 association by binding to distinct 
domains of LRP that are not required for Wnt/Fz interaction (Mao et al., 2001; Bafico et al., 
2001; Semenov et al., 2001; Nusse, 2001). The presence of the co-receptor LRP appears to 
specify Wnt signaling to the Wnt/ß-catenin pathway, because LRP5/6 could not be shown to act 
in other Wnt signaling pathways (Wehrli et al., 2000). This points to an important role for Dkk-
1 as a specific inhibitor of canonical Wnt/ß-catenin signaling (Semenov et al., 2001; Zorn, 
2001). In contrast, other Wnt antagonists are believed to bind directly to the Wnt protein thus 
inhibiting the binding of Wnts to the Wnt receptor complex. Based on this idea, these 
antagonists are thought to inhibit both, canonical and noncanonical pathways (Kawano and 
Kypta, 2003).  
Another component of Dkk action is the presence of yet another transmembrane receptor family 
called Kremen receptors (Krm). Krm-1 and Krm-2 are high-affinity Dkk-1 and Dkk-2 
receptors. In the case of Dkk-1, formation of a ternary complex consisting of Krm, Dkk-1 and 
LRP6 leads to rapid endocytosis and thus removal of the Wnt receptor LRP from the plasma 
membrane. This leads to inhibition of wnt signaling through absence of the co-receptor for Wnt 
signaling (Mao et al., 2002; Rothbächer & Lemaire, 2002) (Fig.3).  
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Figure 3 Dkk-1 exerts its inhibitory function on canonical Wnt signaling through two membrane  
receptors, LRP 5/6 and Kremen. Binding of Dkk-1 to LRP5/6 and Kremen leads to endocytosis of the ternary 
complex. Thus, the co-receptor LRP 5/6, which is required for positive Wnt signaling, is removed from the cell 
surface resulting in inhibition of canonical Wnt signaling.  
 
Dkk-1 expression seems to be regulated by a negative feedback loop in Wnt signaling. 
Recently, it could be shown that human Dkk-1 is a target gene of ß-catenin/TCF and that active 
canonical Wnt signaling induced Dkk-1 transcription (Niida et al., 2004; González-Sancho et 
al., 2005).  
 
2.5. Wnt target genes 
A role for Wnt signaling in cardiovascular disease and the vasculature has only recently been 
recognized. Therefore, relatively few studies are currently available that address the 
connections between downstream components of the Wnt signaling pathway, Wnt target genes 
and their function in cardiovascular disease and the vasculature. However, among the target 
genes of Wnt signaling are several genes that are known to have a function in the vasculature 
and angiogenesis.  
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Some of the matrix metalloproteinases (MMPs) that are thought to play a role in angiogenesis 
are Wnt targets. By degrading matrix molecules, MMPs help to loosen periendothelial support 
that allows endothelial cells to emigrate from their original site to form new vessels (Carmeliet, 
2000; Davis & Senger, 2005). MMP-7 was shown to induce proliferation of endothelial cells in 
vitro. In vascular smooth muscle cells, fibronectin, an extracellular matrix protein, could be 
found to promote proliferation. Cyclin D1 is a cell cycle factor that responded to Wnt signaling 
in vascular smooth muscle cells. C-myc and cyclooxygenase-2(Cox-2), other targets of Wnt 
signaling, are able to induce endothelial cell migration and angiogenesis in vivo (Goodwin & 
D´Amore, 2002).  
Most prominently among the Wnt target genes involved in angiogenesis is VEGF. VEGF could 
be shown to be up-regulated by Wnt signaling/ß-catenin in colon cancer cells and skeletal 
myocytes (Zhang et al., 2001; Easwaran et al., 2003; Kim et al., 2006). VEGF is known to play 
a crucial role in endothelial cell proliferation, migration and survival as well as in physiological 
and pathological angiogenesis (Ferrara et al., 2003).  
 
2.6. Wnt signaling in cardiovascular disease and the vasculature 
Recently, a role of Wnt/ß-catenin signaling in cardiovascular diseases has been emphasized. 
Components and inhibitors of the Wnt signaling pathway have been shown to be involved in 
wound healing after myocardial infarction (e.g. Fz2, Dvl1, ß-catenin, FrzA/sFRP1) (van Gijn et 
al., 2002; van Gijn et al., 1997; Blankesteijn et al., 1999; Blankesteijn et al., 1997; Chen et al., 
2004; Barandon et al., 2003), in cardiac hypertrophy (e.g. GSK-3ß, ß-catenin)(Hardt & 
Sadoshima, 2002; Haq et al., 2000; Masuelli et al., 2003), heart failure (e.g. sFRPs) (Schumann 
et al., 2000) and arterial injury (e.g. FrzB, Fz1, Fz2) (Mao et al., 2000) . 
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Similarly, in the vasculature, many components of the Wnt signaling pathway are found. In 
vitro, vascular cells like endothelial cells and smooth muscle cells express several Wnts and 
Fzs. Additionally, it could be shown that endothelial cells proliferate when stimulated by 
canonical Wnts, whereas noncanonical Wnts have no such effect (Wright et al., 1999; Goodwin 
& D´Amore, 2002).   
There is also evidence for a role of Wnt/ß-catenin signaling in angiogenesis. ß-catenin is the 
center of the canonical Wnt signaling cascade and is thought to have a dual role. Firstly, ß-
catenin controls gene transcription and cell proliferation. Secondly, ß-catenin participates in the 
regulation of cell adhesion by connecting cadherins through α-catenin to the actin cytoskeleton 
(Nelson & Nusse, 2004). These two major features of ß-catenin link it to angiogenesis since 
angiogenesis depends on proliferation and migration of endothelial cells, which in turn requires 
the disruption of cell-cell contacts. These considerations concerning the role of ß-catenin in 
angiogenesis are supported in recent studies. GSK-3ß and the GSK-3ß/ß-catenin axis were 
shown to regulate angiogenesis in endothelial cells. ß-catenin promoted angiogenesis in 
endothelial cells by activating VEGF (Kim et al., 2002; Skurk et al., 2005).  
In early angiogenesis, endothelial cell contacts need to loosen in order to allow the cells to 
migrate into newly formed vessels. In endothelial adhesion, vascular endothelial (VE)-cadherin 
at adherens junctions is connected to the actin cytoskeleton through ß-catenin (among other 
factors) (Liebner et al., 2006). VEGF is able to induce tyrosine phosphorylation of ß-catenin in 
endothelial cells which is accompanied by reorganization of adherens junctions that contain ß-
catenin and endothelial barrier dysfunction. It could be shown that 3 hrs after induction of 
angiogenesis by VEGF, ß-catenin and vascular endothelial (VE)-cadherin were lost from 
regions of endothelial cell-cell contacts consistent with loosened cell contacts (Cohen et al., 
1999; Wright et al., 2002). These observations show a close link between ß-catenin and VEGF. 
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On one hand, VEGF is a target gene of Wnt/ß-catenin signaling and on the other hand ß-catenin 
in cell adhesion sites is regulated by VEGF mediated phosphorylation in endothelial cells. 
In vivo, ß-catenin could also be shown to be involved in angiogenesis. Accumulation of 
cytosolic and nuclear ß-catenin was observed in proliferating vessels of rat N-ethyl-N-
nitrosurea-induced gliomas, in proliferating vascular cells of glioblastoma multiforme, 
medulloblastoma and other central nervous system tumors (Yano et al., 2000a; Yano et al., 
2000b; Eberhart et al., 2000). In contrast to that, adult vessels, i.e. quiescent vessels, show no 
significant levels of cytosolic and nuclear ß-catenin (Goodwin & D´Amore, 2002).  
An animal model of hind limb ischemia revealed an increase of ß-catenin expression in the 
ischemic tissue. Overexpression of ß-catenin in the ischemic tissue led to increased 
angiogenesis and restoration of blood flow (Kim et al., 2006). During neovascularization after 
myocardial infarction, ß-catenin and APC are found in the cytoplasm of vascular endothelial 
cells in newly formed vessels. Dvl-1 expression is also observed in endothelial cells of larger 
arteries in the infarcted area implying a role of Wnt/ß-catenin signaling in neovascularization 
(Blankesteijn et al., 2000). 
 
2.7. Wnt antagonism and angiogenesis 
There is evidence that positive Wnt/ß-catenin signaling can promote angiogenesis. In contrast 
to that, inhibition of Wnt signaling is thought to be associated with vessel stability or vessel 
regression (Goodwin and D´Amore, 2002). However, the role of Wnt inhibition in angiogenesis 
and cardiovascular disease is not yet clear. Nevertheless, there are clues that point to a role of 
Dkk-1 in the vasculature.  
Maintenance and formation of vessels depend on a close interplay between endothelial survival 
and apoptosis. Activated endothelial cells proliferate and migrate to form new vessels. After the 
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formation of new vessels is completed, endothelial cells become quiescent and survive for a 
long time. One of the major factors in endothelial survival is VEGF. It has been shown that 
endothelial survival, mediated by VEGF, is linked to the interaction of VEGF-receptor2 
(VEGFR2), ß-catenin and VE-cadherin. Endothelial survival is in contrast to endothelial 
apoptosis, which occurs in vascular regression (Carmeliet, 2000; Carmeliet et al., 1999; 
Dimmeler & Zeiher, 2000). Dkk-1 was shown to possess pro-apoptotic properties and a tumor 
suppressing function in tumor cell lines (Wang et al., 2000; Shou et al., 2002). Wnt signaling is 
not only implicated in endothelial cell proliferation required in angiogenesis, but also in 
neoplastic cell proliferation. Wnts themselves have been described to be proto-oncogenes. Mis-
regulation of Wnt signaling and mutations of distinct Wnt components lead to cancer (Polakis, 
2000; Peifer & Polakis, 2000). It could be demonstrated that Wnt1 promoted cell survival and 
mediated anti-apoptotic signaling through ß-catenin activation (Chen et al., 2001). Wnt-induced 
cell proliferation could be shown to be inhibited by Dkk-1 (Fedi et al., 1999). 
In the induction of heart formation in vertebrates, Wnt antagonists such as Dkk-1 and Crescent 
have an important role (Schneider & Mercola, 2001; Marvin et al., 2001; Harvey, 2002; Olson, 
2001). Interestingly, Wnt/ß-catenin signaling was involved in proliferation of endocardial cells 
that represent a special endothelial layer of the inner heart. Wnt signaling participated in the 
formation of endocardial cushions and helped regulating cardiac valve formation. In these 
experiments, Dkk-1 was able to block endocardial cushion formation pointing to a possible role 
for Dkk-1 in blocking endothelial cell proliferation (Hurlstone et al., 2003). In mouse 
embryogenesis, Dkk-1 is spatially expressed in the heart (bulbis cordis, endocardium, septum 
transversum, endocardial cushion) and big vessels such as aorta (Monaghan et al., 1999). There 
are no accounts, however, concerning the expression of Dkk-1 in adult vessels and its role in 
angiogenesis.   
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2.8. Project of the thesis 
A growing body of evidence supports the hypothesis that active canonical Wnt signaling is one 
of the pathways promoting angiogenesis. In recent work, it has been emphasized that ß-catenin, 
the central component of canonical Wnt signaling, plays an important role in promoting 
endothelial cell proliferation, endothelial cell migration and angiogenesis. In contrast, inhibition 
of Wnt signaling is thought to be associated with vessel stability and vessel regression. 
Dickkopf-1 (Dkk-1) is a well-characterized and potent inhibitor of Wnt signaling which is 
thought to specifically antagonize canonical Wnt signaling. However, there is little known 
about Dkk-1 and its role in the adult vasculature and endothelial cells. In the present work, we 
addressed the following questions:  
1) What is the role of Dkk-1 in endothelial cells? 
a) Is Dkk-1 expressed in progenitor and mature endothelial cells? 
b) Does the expression of Dkk-1 change when cells are activated or when cells are challenged 
with a strong angiogenic stimulus such as hypoxia? 
c) Does Dkk-1 overexpression in endothelial cells have an impact on the expression of  
factors associated with promotion of angiogenesis such as ß-catenin and VEGF? 
2) Is Dkk-1 expressed in vessels in vivo and, is it found in the endothelium? 
3) What expression pattern of Dkk-1 is observed in a model of ischemic stroke in mice especially 
in the penumbra? Is ß-catenin expressed in the penumbra parallel to the observations made in 
myocardial infarction (Blankesteijn et al., 2000)? 
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3. Materials and Methods 
3.1.  Materials 
3.1.1.  Instruments 
Item Company, Type 
Bacterial incubator  Heraeus, B 6200 
Bacterial shaker New Brunswick Scientific, innova 4330 
Cell counting chamber GLW 
Cell culture incubator Forma Scientific, CO2 water jacketed incubator series II 
Culture Hood Clean Air 
Digital camera Zeiss Axiovert 200M digital camera, Carl Zeiss 
Electrophoresis power supply GibcoBRL PS 305, GIBCO invitrogen 
Electrophoresis unit Wide Mini-Sub Cell RT electrophoresis system,  
BIO-RAD 
Fine scale SBC 21, Scale Tec 
Freezers -20 °C (Liebherr); -80 °C (Revco) 
Heat block Thermomixer comfort 1.5 ml, eppendorf 
Mega centrifuge J-6B, Beckman; Megafuge 1.0, Heraeus;  
RC 5B plus, Sorval 
Microscope Eclipse TE300, Nikon; Carl Zeiss 
Microscope slides and cover 
glasses 
SuperFrost Plus, Menzel and microscope cover glasses,  
Menzel 
Mini centrifuge Mikro 20, Hettich 
Parafilm M American National Can 
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Pap Pen (for immunostaining) SCI Science Services 
pH meter Microprocessor, WTW 
Photo software Openlab, Photoshop 
Pipettes 2 µl, 20 µl, 200 µl, 1000 µl pipetman, Gilson; Multipette 
plus, Eppendorf; Pipetboy acu, IBS Integra Biosciences  
Pipette tips disposable graduated filter tips, DNase, RNase, pyrogen 
 free, starlab; Combitips plus 0,2 ml, Eppendorf 
Plastic pipettes 2ml, 5ml, 25ml, 50ml stripette, Corning 
Polaroid camera Mitsubishi electric 
Refrigerator 4°C (Liebherr) 
Shakers Unimax 2010, Heidolph 
Scale BP2100S, BP310S, Sartorius 
Software for primer selection MacVector 
Spectrophotometer Biophotometer 6131, eppendorf 
Thermal cycler PTC-100 Peltier, MJ Research 
Tissue cutter Jung Frigocut 2800E Cryostat, Leica 
Tubes Blue Max 50 ml Polypropylene Tube,  
Falcon; 14 ml Polypropylene Round-Bottom Tube  
17 x 100 mm style Nonpyrogenic, Falcon; Thermo 
Tube TM PCR Tubes 0.2 ml; peqlab biotechnologie; 
1.5 ml safe lock tubes, eppendorf 
Vortex  JK MS2 Minishaker, IKA 
Water bath C20CS edition2000, Lauda 
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3.1.2. Reagents and general materials   
Items Company 
1 kb DNA ladder Invitrogen 
100 bp DNA ladder New England Biolabs 
2-mercaptoethanol Sigma 
Acetone Merck 
Agarose, electrophoresis grade invitrogen 
all-trans retinoic acid Sigma 
Bacto-Agar Roth 
Bacto-tryptone DIFCO 
BamHI  (20 000U/ml) New England Biolabs 
Boric acid Sigma 
Bovine serum albumin (BSA) ICN Biomedicals 
Bromphenolblue Sigma 
BSA purified (100 x; 10mg/ml;  
for restriction digest) 
New England Biolabs 
Calciumchloride (CaCl2) Sigma 
dibutyryl cyclic AMP Sigma 
Dimethylsulfoxide (DMSO) Sigma 
DNase (from RNeasy Mini Kit) Qiagen 
dNTP (20 mM; 500µl) Amersham 
EcoRI buffer New England Biolabs 
EcoRI (20 000U/ml) 
 
New England Biolabs 
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Ethylenediaminetetraacetic acid  
(EDTA) 
Sigma 
Ethanol Merck 
Ethidiumbromide Merck 
Gelatine (porcine skin) Sigma 
Glycerine Roth 
Isopropanol Merck 
Kanamycin Sigma 
Ligase buffer for T4 Ligase New England Biolabs 
Magnesiumchloride (MgCl2) Merck 
Mo-MLV Reverse  
Transcriptase (200U/µl) 
GIBCO Invitrogen 
Oligo (dt)15 Primer 20µg 500µg/ml Promega 
Potassiumacetate Merck 
Potassiumchloride (KCl) Sigma 
Potassiumdihydrophosphate  
(KH2PO4) 
Merck 
RNase A (from EndoFree  
Plasmid Maxi Kit) 
Qiagen 
Rnase Roche 
Rnasin RNase inhibitor  
(2500U; 40U/µl) 
Promega 
Saccharose Sigma 
Sodiumchloride (NaCl) Sigma 
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Sodiumdihydrophosphate (NaH2PO4) Merck 
Sodiumdodecylsulphate (SDS) Merck 
Sodiumhydroxide (NaOH) Sigma 
T4 DNA Ligase New England Biolabs 
Taq DNA Polymerase (5 U/µl) Promega 
TissueTek tissue embedding medium Sakura Finetek 
Tris-(hydroxymethyl)-aminomethane 
(Tris) 
Roth 
Trypsin-EDTA GIBCO Invitrogen 
Tween 20 Merck 
Vectashield mounting medium Vector laboratories 
Vent DNA Polymerase (2000U/ml) New England BioLabs 
Xylencyanol Sigma 
Yeast extract Life Technologies 
 
3.1.3. Cell lines and bacteria strains 
Cell line Reference 
HUVECs Human umbilical vein endothelial  
cells, Cambrex 
eEPCs Mouse embryonic endothelial  
progenitor cells, Hatzopoulos et al., 1998 
DH5α E.coli bacterial cells, GIBCO Invitrogen 
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3.1.4. Cell culture media 
3.1.4.1 eEPC medium 
DMEM EPC day 7.5 Medium (end volume 500ml) 
Medium contained 77% (385 ml) of DULBECCO´S MEM with 25 mM HEPES, 20% (100 ml) 
of Fetal Bovine Serum, 3.5 µl per 500 ml of 2-mercaptoethanol, 1% (5 ml) of 200 mM L-
glutamine (100x), 1% (5 ml) of Penicillin/Streptomycin (10.000 units/ml Penicillin, 10 mg/ml 
Streptomycin) and 1% (5 ml) of non-essential amino acids MEM. 
 
3.1.4.2 HUVECs medium 
For HUVECs EBM®-2 (Cambrex) was used (end volume 500ml). Medium contains basal 
medium for human endothelial cells without bovine brain extract (BBE) and a final FBS (fetal 
bovine serum) concentration of 2%. The medium further contains 0.04% Hydrocortisone,  
0.4% hFGF, 0.1% hEGF, 0.1% GA-1000 (Gentamicin, Amphotericin-B), 0.1% VEGF,  
0.1% R3-IGF-1, 0.1% Ascorbic Acid, 0.1% Heparin (all purchased from Cambrex).  
 
3.1.4.3 LB (Luria-Bertani) medium 
1% Bacto-tryptone  
1% NaCl  
0.5% Bacto-yeast extract   
10 g Bacto-tryptone, 5 g Bacto-yeast extract and 10 g NaCl were dissolved in 800 ml distilled 
water. pH was adjusted to 7.0 with NaOH and volume was adjusted to 1 liter with distilled 
water. To sterilize, autoclaving was performed. For LB plates, 15 g Bacto-agar was added.   
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3.1.5. Cell culture materials 
Item Company 
Lipofectamine 2000 TM Life Technologies, Inc., 
Cell culture dishes NUNC 
Cell scraper Sarstedt 
DMEM with 25mM HEPES GIBCO Invitrogen 
Fetal bovine serum (FBS) GIBCO Invitrogen 
L-glutamine GIBCO Invitrogen 
Non-essential amino acids MEM GIBCO Invitrogen 
Penicillin/Streptomycin GIBCO Invitrogen 
EBM-2 BulletKit Cambrex 
     
 
3.1.6. Primary antibodies 
Anti-Dkk-1 antibody 
Anti-human DKK-1 Antibody 0.1 mg/ml; human specific goat IgG; R&D systems 
 
Anti-ß-catenin antibody 
Anti-ß-catenin developed in Rabbit Delipidized, whole Antiserum; 56 mg/ml; Sigma 
 
Anti-neuronal nuclei (NeuN) antibody 
Mouse Anti-neuronal nuclei (NeuN) monoclonal antibody 1 mg/ml reacts with human, mouse, 
rat, ferret, chick and salamander; Chemikon 
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Anti-glial fibrillary acidic protein (GFAP) antibody 
Mouse Ant-glial fibrillary acidic protein (GFAP) monoclonal antibody reacts with human, pig 
and rat; Chemikon 
 
Anti-CD31 (PECAM-1) antibody 
Purified rat anti-mouse CD31 (PECAM-1) Monoclonal antibody; BD Pharmingen 
 
Anti-actin antibody 
Actin, Smooth Muscle Specific (ab-2), mouse monoclonal antibody; Oncogene 
 
 
3.1.7. Secondary antibodies 
Anti -rat 
Cy TM-conjugated AffiniPure Donkey Anti-Rat IgG (H+L) 1.5 mg/ml; Dianova  
Fluorescein (FITC)-conjugated AffiniPure Donkey Anti-Rat IgG (H+L) 1.5 mg/ml; Dianova 
Alexa Fluor® 488 goat anti-rat IgG (H+L) 2 mg/ml; Molecular Probes MoBiTec 
 
Anti-goat 
Cy TM-conjugated AffiniPure Donkey Anti-Goat IgG (H+L) 1.5 mg/ml; Dianova 
Fluorescein (FITC)-conjugated AffiniPure Donkey Anti-Goat IgG (H+L) 1.5 mg/ml; Dianova  
Alexa Fluor® 568 donkey anti-goat IgG (H+L) 2 mg/ml; Molecular Probes MoBiTec 
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Anti-rabbit 
Cy TM-conjugated AffiniPure Donkey Anti-Rabbit IgG (H+L) 1.5 mg/ml; Dianova  
Fluorescein (FITC)-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) 1.5 mg/ml; Dianova 
Alexa Fluor® 488 goat anti-rabbit IgG (H+L) 2 mg/ml; Molecular Probes MoBiTec  
Alexa Fluor® 568 goat anti-rabbit IgG (H+L) 2 mg/ml; Molecular Probes MoBiTec 
 
Anti-mouse 
Fluorescein (FITC)-conjugated AffiniPure Donkey Anti-Mouse IgG, Fc fragment specific 1.4 
mg/ml; Dianova 
Alexa Fluor® 488 goat anti-mouse IgG (H+L) 2 mg/ml; Molecular Probes MoBiTec 
 
 
 
3.1.8. RT-PCR Primer 
Mouse primer 
Dkk-1 CAACTACCAGCCCTACCCTTGCG (forward 5´to 3´) 
  CAGACGGAGCCTTCTTGTCCTTTG (reverse 3`to 5`) 
 
ß-catenin CGAAGGGTGTACTGGAGCTCTC
  GTCCAGTCCAAGATCTGCAGTCTC 
 
Vegf GGATCCATGAACTTTCTGCT
  GGGTGCACTGGACCCTGGCT 
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ß-actin CTACGAGGGCTATGCTCTCCC
  CCGGACTCATCGTACTCCTGC 
 
Human primer 
DKK-1 AGACCATTGACAACTACCAGCCGTA
  GTTCTTCTGGAATACCCATCCAAGG 
 
ß-catenin GCTTAGCTGAGCTTAGATGATAG 
  TGATGATTGCTCATCATGATAGTA 
 
VEGF CAAGTGGTCCCAGGCTGCACCC 
  CCCTGAGGAGGCTCCTTCCTGCC 
 
GAPDH AGAACATCATCCCTGCCTCTACTG 
  TGTCGCTGTTGAAGTCAGAGGAGA 
 
LRP 6 ATCATGTCATGCTACTCATCGAT
  GCATACTGCTATGGCTATCTGC 
 
Human/Mouse primer 
Aldolase AGCTGTCTGACATCGCTCACCG 
  CACATACTGGCAGCGCTTCAAG 
 
All primers were synthesized by MWG-Biotech.  
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3.1.9. Cloning primers for human Dkk-1 
CGGGATCcttctgagatgatggctctgggcgc   forward primer + BamHI 
GGAATTCggatagctggtttagtgtctctgac  reverse primer + EcoRI 
(Restriction sites are indicated in capital letters) 
Cloning primers were synthesized by MWG-Biotech.  
 
3.1.10. Kits 
RNeasy® Mini Kit (for RNA isolation)  Qiagen 
RNase-Free DNase Set    Qiagen 
QIAquick® PCR purification Kit   Qiagen 
Qiagen®EndoFree Plasmid Maxi Kit   Qiagen 
M.O.M kit TM for detecting mouse 
primary antibodies on mouse tissue   Vector Laboratories, Inc. 
 
 
 
3.1.11. Plasmids 
pBK-CMV phagemid 4518bp    Stratagene 
pBK-CMV-DKK-1    created in this work 
 
3.1.12. Solutions 
 
Blocking buffer (for antibody staining) 
1.5% BSA in 1x PBS 
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Buffer NX 10x (for reverse transcription) 
2M KCl,  
1M Tris-Cl pH 8.4,  
1M MgCl2 ,  
3% Tween 20 
 
Buffer 10x (for RT-PCR) 
0.1 M Tris-Cl pH 8.4,  
0.5 M KCl,  
15 mM MgCl2  
 
10 x DNA gel loading buffer 
40% (w/v) saccharose 
0.25% bromphenolblue 
0.25% xylencyanol 
 
 
Phosphate-Buffered Saline (PBS) 20x 
136 mM NaCl,  
2.6 mM KCl,  
10 mM NaH2PO4,  
1.5 mM KH2PO4, pH 7.4 
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10x Tris-Borate-EDTA (TBE) 
108 g Tris base 
55 g boric acid 
20 ml 0.5 M EDTA, pH 8.0 
Volume was adjusted to 1l with H2O. 
 
Buffer P1 (resuspension buffer) 
50 mM Tris-Cl, pH 8.0 
10 mM EDTA 
100 µg/ml RNase A 
 
Buffer P2 (lysis buffer) 
200 mM NaOH 
1% SDS (w/v) 
 
Buffer P3 (neutralization buffer) 
3.0 M potassium acetate, pH 5.5  
 
 
 
Buffers included in Qiagen Kits 
RLT   included in RNeasy Mini Kit (Qiagen) 
RW1   included in RNeasy Mini Kit (Qiagen) 
RPE   included in RNeasy Mini Kit (Qiagen) 
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RDD   included in RNase-Free DNase Set (Qiagen) 
ER    included in EndoFree Plasmid Maxi Kit (Qiagen) 
QBT   included in EndoFree Plasmid Maxi Kit (Qiagen) 
QC    included in EndoFree Plasmid Maxi Kit (Qiagen) 
QN    included in EndoFree Plasmid Maxi Kit (Qiagen) 
TE    included in EndoFree Plasmid Maxi Kit (Qiagen) 
PB    included in QIAquick PCR purification Kit (Qiagen) 
PE    included in QIAquick PCR purification Kit (Qiagen) 
EB    included in QIAquick PCR purification Kit (Qiagen) 
 
3.2.  Methods 
3.2.1. Cell culture and bacterial cultures 
3.2.1.1 Maintenance of cells in culture 
All cells were incubated and maintained at 37°C, 5% CO2 and 21% O2. Culturing of the cells 
was carried out on NUNCLON plates that were 6 cm or 10 cm in diameter. For better 
attachment of eEPCs to the plates, the plates were incubated with 4 ml or 12 ml of 0.1 % gelatin 
for at least 20 minutes at 37°C before use. 
Embryonic EPCs and HUVECs were maintained in DMEM EPC day 7.5 Medium and 
HUVECs medium (EBM-2), respectively. When the cell layer on a plate reached about 90% 
confluency, the cells were passaged in a ratio appropriate for each cell type. Tissue culture 
work was performed in a sterile tissue culture bank. All materials used in the culture bank were 
sterilized with 70% ethanol or UV light for 15 minutes to avoid contamination. 
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3.2.1.2 Passaging of cells 
To split cells that had reached about 90% confluency, the cell layer was washed with 6 ml 1x 
PBS. The cells were then incubated 5-7 minutes with 1x Trypsin-EDTA to detach them from 
the plates. Treatment with Trypsin was stopped with 5 ml Medium. The cell suspension was 
transferred from the plates to a sterile tube and then spun at 1200 rpm for 5 minutes. After 
spinning, the supernatant was removed and cells were resuspended in fresh medium and placed 
in new plates. 
 
3.2.1.3 Differentiation of eEPCs in vitro by cAMP and retinoic acid 
eEPCs maintained in culture as described above, were differentiated by adding 1 µM all-trans 
retinoic acid (RA) and 0.5 mM dibutyryl cyclic AMP (cAMP). eEPCs were treated with RA 
and cAMP for 4 days. The changes in cell morphology were monitored by microscopy. 
 
3.2.1.4 Stimulation of eEPCs and HUVECs by hypoxia 
eEPCs and HUVECs were cultured under normoxic (21% O2) and hypoxic (2% O2) conditions 
as described before (Wei et al., 2004). Successful stimulation of eEPCs and HUVECs was 
monitored by an induction of VEGF expression. VEGF mRNA was detected by RT-PCR using 
Aldolase as a control.  
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3.2.1.5 Lipofectamine transfection 
For transfection of HUVECs, cells in passage 4 or 5 with a confluency of 80 – 90% were used. 
HUVECs were grown in their normal growth medium containing EBM-2 basal medium, 
growth factors and gentamycin (see above). For transfection, a special medium containing 
EBM-2, growth factors, but no serum and antibiotics, was prepared. For each culture dish with 
HUVECs to be transfected, 8 µg of DNA was diluted in 1.5 ml serum and antibiotic free EBM-
2 medium. 16 µl of lipofectamine was diluted in 1.5 ml of serum and antibiotic free EBM-2 
medium and added to the diluted DNA. Incubation was allowed for 30 minutes at room 
temperature to form DNA-lipofectamine complexes for transfection. The DNA-lipofectamine 
mixture was then added to the cells. Cells were incubated at 37 °C for 3 hrs and transfection 
was then stopped by adding normal growth medium to the plates. Cells were lysed 24 hrs after 
the start of transfection for molecular analysis.   
 
3.2.1.6 Lysis of cells 
Cells growing in monolayers on cell-culture plates were lysed directly in the culture dishes. 
Medium was removed and the cells were washed twice with 1x PBS. Depending on the cell 
number, RLT Lysis buffer plus 2-Mercaptoethanol was added to the plates and incubated for 5 
minutes (5 x 106 cells in 6 cm plates 350 µl RLT; 5 x 106 – 1 x 107 cells in 10 cm plates, 600 µl 
RLT). Cell lysate was collected using a rubber police-man and transferred to 1.5 ml tubes. At 
this point lysates could be kept at -20 °C frozen for storage. 
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3.2.1.7 Competent bacteria 
Highly competent E.coli are needed for transforming ligation products. In E. coli, treatment 
with ice-cold CaCl2 creates a transient state of “competency”, during which, they can take up 
DNA.  
From a single colony of E. coli (DH5α) on a petri dish an overnight preculture was started in 2 
ml LB media by incubating the culture at 37°C and shaking for oxygenation. On the next day, 1 
ml of the preculture was inoculated in 100 ml fresh media and the culture was grown at 37°C 
until the OD at the wavelength of 600 nm reached 0.2 to 0.4. The culture was cooled on ice for 
at least 15 min. The following steps were carried out at 4°C in pre-cooled sterile tubes. Cells 
were spun for 5 minutes at 5000 rpm and supernatant was discarded. Bacterial pellets were 
carefully resuspended in a small volume of ice-cold 100 mM CaCl2. The suspension was 
diluted with the CaCl2 solution to a final volume of 30-40 ml and left on ice for 25 min with 
occasional shaking. Cells were spun down as before, supernatant was discarded and pellets 
were resuspended in 5 ml glycerol/CaCl2. The resulting suspension was aliquoted in 100 to 400 
µl and stored at –70°C.  
 
3.2.1.8 Transformation of competent bacteria 
100 µl of competent E. coli (DH5α) in 1.5 ml tubes were thawed on ice and mixed with 
approximately 40 ng of ligated DNA. This mixture was kept on ice for 30 minutes and then 
heat-shocked for 90 seconds at 42 °C in a thermomixer. The bacteria were put on ice for 
another 2 minutes and 900 µl of antibiotic-free LB-medium was added to the tubes. Bacteria 
cultures were then incubated at 37 °C and 1200 rpm in the thermomixer for 30 - 60 minutes. 
Tubes containing the bacteria cultures were centrifuged for 20 seconds and supernatant was 
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decanted. After resuspension of the pellet, bacteria were streaked on the plates. Selection of 
transformed bacteria was performed by using antibiotic containing (50 µg/ml kanamycin) agar 
plates. Only bacteria that have taken up the right plasmid containing the antibiotic kanamycin 
resistance cassette can grow and form colonies on kanamycin containing plates. Some colonies 
growing on the plates were picked for expansion in LB medium and subsequent DNA 
preparation. 
 
 
3.2.2. RNA techniques  
3.2.2.1 Total RNA isolation (RNeasy® method; RNeasy Mini Kit, Qiagen) 
Lysates from cells (see 3.2.1.6) were transferred onto a QIAshredder spin column placed in a 2 
ml collection tube and centrifuged for 2 minutes at maximum speed to be homogenized. One 
volume (350 µl or 600 µl, respectively) of 70% ethanol was added to the homogenized lysate 
and mixed well by pipetting to adjust the binding conditions. Up to 700 µl of the sample was 
transferred to the RNeasy spin column where the RNA could adsorb to the membrane. The spin 
column was placed in a 2 ml tube and centrifuged for 1 minute at 10 000 rpm. Flow-through 
was discarded. For washing 700 µl buffer RW1 was added to the column and centrifuged for 
another 1 minute at 10 000 rpm. To degrade genomic DNA, 80 µl of DNAse incubation mix 
(10 µl DNase I stock solution plus 70 µl RDD buffer) was applied directly onto the spin column 
membrane. Incubation with DNAse was allowed for approximately 15 minutes at room 
temperature. After treatment with DNAse, the column was washed with 350 µl buffer RW1 for 
1 minute at 10 000 rpm and flow-through was discarded. The column was placed in a new 2 ml 
collection tube. 500 µl RPE buffer was applied to the column, the sample was centrifuged for 1 
minute at maximum speed and the flow-through was discarded. To wash the silica-gel 
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membrane, 500 µl RPE buffer was applied to the column and centrifuged for 3 minutes at 
maximum speed. After discarding the flow-through, the column was again centrifuged for 2 
minutes at full speed to remove residual liquid left from the last washing step. The RNeasy 
column was transferred into a new tube and 50 µl of RNase free water was pipetted directly 
onto the spin column membrane. After 10 minutes, the column was centrifuged at 10,000 rpm 
for 2 minutes to elute the RNA. RNA was immediately put on ice. For long term storage, 
isolated RNA was kept at -80°C. 
 
3.2.2.2 Measurement of RNA concentration 
RNA concentrations were measured by using a UV spectrophotometer at a wavelength of 260 
nm. Absorption of 1.0 at 260 nm corresponds to ~40 µg/ml of RNA.  
 
3.2.2.3 Reverse Transcriptase (RT) reaction 
Reverse Transcription (RT) was used to synthesize cDNA for RT-PCR. Reverse transcriptases 
with RNA-dependent DNA polymerase activity synthesize complementary DNA (cDNA). 
Isolated RNA served as a template for Polymerase Chain Reactions (PCR).  
For the RT-reaction, 3 µg of RNA was diluted in ddH2O up to a total volume of 15 µl. 3.75 µl 
of oligo-dT primer was added to the tubes. In order to open up secondary structures of the RNA 
and to make poly A tails of mRNA accessible for binding to oligo-dT primers, the mixture was 
incubated at 65°C for 5 minutes. To avoid refolding of the RNA, tubes were immediately put on 
ice. To start the RT-reaction, 11.25 µl of RT-Mix was pipetted into the tubes and the mixture 
was incubated at 37°C for 55 minutes.  
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RT-Mix contained:  
4.5   µl NX buffer 
1.5   µl dNTPs 
3.0   µl 2-mercaptoethanol 
0.75 µl RNasin 
1.5   µl Mo-MLV Reverse Transcriptase 
11.25 µl 
To stop the enzymatic reaction, the mixture was incubated at 95°C for 5 minutes. Finally, 270 
µl of ddH20 was added to the tubes. The final volume was 300 µl and cDNA had a 
concentration of approximately 10 ng/µl. 
 
3.2.3. DNA techniques 
3.2.3.1 Design of oligonucleotide primers for RT-PCR 
RT-PCR primers for mouse and human Dkk-1 were designed based on the corresponding 
mouse and human gene sequences, respectively (mouse Dkk-1 Acc.no. AF 030433, 
www.ncbi.nlm.nih.gov, human DKK-1 Acc.no. AF 127563, www.ncbi.nlm.nih.gov). For 
selecting RT-PCR primer pairs, the computer program MacVector was used. This software 
program helps to analyze the secondary structure (e.g. hairpins) and annealing temperatures of 
PCR primers. It was also used to compare the homology between the target DNA and 
sequenced DNA. Characteristics such as the isoelectric point (IP), molecular weight (MW) 
were also analyzed. Additionally, BLAST (Basic Local Alignment Search Tool) analysis of the 
different primer pairs using the NCBInr Database (National Center for Biotechnology 
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Information, www.ncbi.nlm.nih.gov/BLAST/) was carried out to ensure that the newly 
designed primer pairs were gene-specific.  
Oligonucleotid primers were commercially synthesized and delivered in a lyophilised form. All 
primers were dissolved in sterile water to obtain a final concentration of 100 pmol/µl.  
 
3.2.3.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Gene expression was determined by means of RT-PCR using gene-specific primers and cDNA 
as a template (analytical amplification). For the amplification of long DNA fragments for 
cloning purposes, the Vent DNA Polymerase with a high proof-reading cabability was used.  
The Master Mix for amplification contained:  
12.68  µl H2O 
  1.0    µl DMSO 
  0.2    µl dNTP 
  2.0    µl 10x buffer 
  2.0    µl primer pair (each 5 µM ) 
  0.12  µl DNA Polymerase  
18.00  µl 
18 µl of the Master Mix was added to 2 µl cDNA (10 ng/µl). 
The PCR amplification was performed according to the following protocol by varying the 
annealing temperatures and the elongation times:  
Step 1 Initial denaturation: 94°C for 1 minute 
Step 2 Denaturation: 94°C for 30 seconds 
Step 3 Annealing: 60-65°C for 1 minute 
Step 4 Elongation: 72°C for 1 minute 
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Step 5  back to step 2 
Step 6 Final elongation: 72°C for 5 minutes 
Step 7 keep samples at 4° C 
 
3.2.3.3 Agaraose gel electrophoresis of DNA 
The separation of DNA fragments according to their size was performed by gel electrophoresis 
on 1.5% agarose gels. For the gel, 1.5 g agarose was added to 100 ml 1x TBE buffer. The 
mixture was boiled in the microwave to solubilize the agarose and then poured into the gel tray. 
The gel was left for 30 minutes to polymerize before it was used for electrophoresis. 
Electrophoresis was carried out in gel chambers in 1x TBE electrophoresis buffer. DNA gel 
loading buffer was added to the DNA samples and these were loaded onto the gel; a well was 
loaded with a 100 bp or 1kb ladder to determine the size of the DNA fragments. Gels were run 
at 60 – 90 V. After the separation of DNA fragments was completed, gels were stained in a 
0.02% ethidium bromide solution for 10 minutes. The gels were photographed under UV light 
using a Polaroid camera.  
 
3.2.4. Cloning into plasmid vectors 
3.2.4.1 Construction of Dkk-1 gene expression vector 
The full-length human DKK-1 cDNA was amplified by PCR and cloned into the multiple 
cloning site (MCS) of the pBK-CMV vector. The primers were designed based on the human 
DKK-1 sequence (NCBI Acc. no. AF 127563 www.ebi.ac.uk). The sense primer was designed 
to include the start codon and the antisense primer included the stop codon, respectively. Both 
primers contained a restriction enzyme recognition sequence, that was not present elsewhere in 
the gene, but was present in the MCS of the vector. To verify this, a restriction summary and 
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the vector map were compared (Restriction summary: The sequence manipulation suite 
www.bioinformatics.org/sms/). Oligonucleotide primers were commercially synthesized and 
dissolved in sterile water to obtain a 100 pmol/µl solution. Primers were tested by RT-PCR. 
PCR products were run on an electrophoresis gel and compared to a 1 kb ladder to ensure, that 
the PCR products had the correct sizes. PCR products were then digested with the appropriate 
restriction enzymes and thereafter purified using the QIAquick PCR purification Kit to remove 
enzymes and other agents. The insert was then ligated into the expression vector, which had 
been digested with the same enzymes as the PCR product, by using T4 DNA ligase. The 
products of ligation were then transformed in E. coli, which were plated on appropriate 
selection agar plates. Single transformed colonies were expanded in bacterial cultures for Mini-
preparation. The resulting purified DNA was used for restriction digestion analysis. For 
sequencing of the plasmid and transfection into cells, Maxi-Preparation was performed, to 
obtain sufficient amounts of plasmid DNA.  
 
3.2.4.2 Purification of DNA (QIAquick PCR purification kit) 
During the process of purification, small molecules and proteins pass through a column while 
DNA adsorbes to the silica-membrane of the column. Finally, pure DNA is eluted with Tris 
buffer or H2O. To 1 volume of the PCR sample 5 volumes of buffer PB were added. The 
sample was applied to the QIAquick spin column sitting in a 2 ml collection tube and 
centrifuged for 30-60 seconds at 13 000 rpm. Flow-through was discarded and 0.75 ml buffer 
PE was pipetted to the column and centrifuged for 30-60 seconds. Flow-through was again 
discarded and the column and collection tube were centrifuged for another 60 seconds to 
remove residual liquids. To elute the DNA, the column was placed in a new 1.5 ml 
microcentrifuge tube, 30 µl of buffer EB was pipetted onto the center of the QIAquick 
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membrane. The column was centrifuged for 60 seconds and flow through was not discarded. 
Another 30 µl of buffer EB was added to the center of the column and centrifuged for 60 
seconds. Purified DNA was kept at -20°C.  
 
3.2.4.3 Digestion of DNA with restriction endonucleases 
Within double strand DNA, particular restriction endonucleases recognize and cleave usually 4-
6 base pairs specific sequences creating, cohesive ends. The restriction digest was performed 
according to the manufacturer’s recommendations for buffer systems and reaction conditions. 
1U of enzyme is needed per 1 µg of DNA to complete digestion in one hour. To ensure 
complete digestion, usually 10 fold excess units were used. Incubation of the digestion mix was 
allowed for 5 hours at 37 °C.  The completion of the reaction was monitored by agarose gel 
electrophoresis. 
 
3.2.4.4 Cohesive-end ligation 
This procedure was performed to ligate DNA inserts with a vector plasmid to create new 
plasmids. DNA fragments were prepared for ligation by restriction digest and following 
purification as described above. The ligation reaction was set up as follows:  
50 ng vector DNA 
X  ng insert DNA 
1   µl T4 DNA ligase 
2   µl ligation buffer 
ddH20 to 20 µl 
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Vector and insert were added at a molar ratio of 1:10. The final volume of the ligation mix was 
20 µl. Incubation was allowed for 2 hrs at 16 °C. Finally, the mixture was heated at 65°C for 10 
minutes to inactivate the enzyme. 
 
3.2.4.5 Mini-preparation of plasmid DNA 
Small scale plasmid preparation was used to check if single bacterial colonies carried a certain 
plasmid. Overnight cultures were grown at 37 °C with shaking at 190 rpm in 2 ml of LB-
medium containing 50 µg/ml of kanamycin. To start Mini-preparation and harvest cells, 
cultures were transferred to 1.5 ml tubes and centrifuged for 20 sec at 13 000 rpm. Supernatant 
was removed and 100 µl of buffer 1 (resupension buffer) was added to the tubes and mixed 
well. 100 µl of buffer 2 (lysis buffer) was pipetted into the tube, gently mixed and incubated for 
5 minutes at room temperature. Next, 100 µl of buffer 3 (neutralization buffer) was added to the 
tube and mixed by gently shaking the tube. After incubating on ice for 3 minutes, tubes were 
centrifuged for 5 minutes at 13 000 rpm. Supernatant was transferred to new 1.5 ml tubes and 
mixed with 600 µl of ice cool 100% ethanol for precipitation. Tubes were kept at -80 °C for 10 
minutes and then again centrifuged for 5 minutes at 13 000 rpm. Ethanol was removed from the 
tube avoiding the pellet. The pellet was air-dried for 10 minutes and then resuspended in 40 µl 
of ddH2O.   
 
3.2.4.6 Maxi-preparation of plasmid DNA 
Maxi preparation of plasmid DNA was carried out with the endotoxin-free EndoFree Plasmid 
Maxi Kit (Qiagen). This special kit minimizes the amount of contaminating bacterial endotoxin 
during DNA isolation. Because endotoxin is known to affect eukaryotic cells and transfection 
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efficiency, removal of endotoxin is critical before DNA is introduced in cells. The general 
procedure of plasmid purification is based on a modified alkaline lysis method.   
Overnight bacterial cultures were started from Mini-preparation cultures containing the 
plasmids. Cultures were grown in 50 ml LB-medium containing 50 µg/ml of kanamycin at  
37°C with shaking at 190 rpm. Bacterial cells were pelleted at 6 000 rpm and 4 °C for  
15 minutes. For lysis of the cells, the pellet was resuspended in 10 ml of buffer P1 
(resuspension buffer). Buffer P2 (lysis buffer) (10 ml) was added and mixed by gently inverting 
the tube. Incubation of P2 was allowed for 5 minutes at room temperature. Meanwhile the 
QIAfilter cartridge was prepared. 10 ml of chilled (4 °C) buffer P3 (neutralization buffer) was 
added to the lysate and mixed gently. The lysate was poured into the QIAfilter cartridge and left 
for 10 minutes to allow precipitate to float to the top of the solution. Filtration was started by 
inserting the plunger into the cartridge. The cell lysate was filtered into a 50 ml collection tube. 
2.5 ml of buffer ER was added to the filtrate, gently mixed and incubated on ice for 30 minutes. 
The filtered lysate was applied to a QIAGEN-tip 500 equilibrated with 10 ml QBT buffer. The 
lysate entered the resin by gravitiy flow. The QIAGEN-tip was washed twice with 30 ml of 
buffer QC. DNA was eluted with 15 ml of buffer QN. Following this, DNA was precipitated by 
applying 0.7 volumes (10.5 ml) of isopropanol to the eluted DNA and centrifuged at 4000 rpm 
for 30 minutes at 4 °C. The DNA pellet was washed twice with 70 %ethanol (96-100% ethanol 
in endotoxin-free water) for 10 minutes at 4 000 rpm. The supernatant was carefully removed 
and the pellet was air-dried for 5-10 minutes. The DNA pellet was dissolved in a suitable 
volume of buffer TE and DNA concentration was determined. 
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3.2.4.7 Measurement of DNA concentration 
DNA concentrations were measured using a spectrophotometer at a wavelength of 260 nm. An 
absorption value of 1.0 corresponds to ~ 50 µg/ml of DNA.  
 
3.2.4.8 Verification of plasmid DNA 
Identity of the plasmid DNA was verified by restriction endonuclease digestion. If plasmid and 
insert were separated correctly by the restriction digest and had the right sizes in an analytical 
gel electrophoresis, plasmid DNA was sequenced. DNA sequencing was performed by 
Sequiserve, Vaterstetten, Germany.  
 
3.2.5. Histology 
3.2.5.1 Tissue sectioning  
Mouse tissues were embedded in OCT Tissue Tek for cryopreservation. Embedded tissues were 
stored at –80°C for further work. Tissue sectioning was carried out with a JUNG FRIGOCUT 
2800E Cryostat. All sections had a thickness of 10 µm. After sectioning, sections were air-dried 
for 30 minutes, fixed in ice cool acetone for 20 minutes at – 20 °C and again air dried for 1- 2 
hrs at room temperature. Finally, sections were stored in dry boxes at - 20 °C for further work. 
 
3.2.5.2 Immunofluorescence 
To detect proteins in tissue sections, immunofluorescence was used. Immunofluorescence is 
based on the binding of a primary monoclonal or polyclonal antibody to its respective antigen. 
Secondary antibodies, conjugated with a fluorescence dye, bind to the primary antibodies. The 
staining of the sections is observed by fluorescence microscopy. 
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For antibody staining of cryopreserved tissue sections, sections were thawed at room 
temperature for 5 to 10 minutes and washed for 10 minutes in 1x PBS. Sections were 
surrounded with a PapPen and washed 5 times with 1x PBS for 10 min. Following this, sections 
were blocked for 1 hour with blocking buffer to ensure that no unspecific antibody binding to 
the tissue sections occurred. Primary antibodies in their respective dilutions were pipetted onto 
sections and incubated O/N at 4°C. The next day, sections were washed 5 times with 1x PBS 
and incubated with the secondary antibody for 1 hour at room temperature. In a last step, the 
sections were washed 5 times with 1x PBS, air-dried for 5 minutes and mounted with 
VECTASHIELD Mounting Medium.   
For detection of mouse primary antibodies (NeuN, GFAP and Actin) on mouse tissues, sections 
were treated with M.O.M kit TM BASIC according to the manufacturer’s recommendations. 
  
3.2.5.3 Microscopy and fluorescence microscopy 
For microscopy and fluorescence microscopy the NIKON Eclipse TE300 Microscope was 
used. The fluorescence colour was observed using a NIKON Super High Pressure Mercury 
Lamp at appropriate wavelengths through the appropriate filters. Sections were photographed 
using a Zeiss Axiovert 200M digital camera. Pictures were processed using photo software 
(openlab®, photoshop®).  
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4. Results  
4.1. Expression of Dkk-1 and ß-catenin in endothelial cells in-vitro  
To investigate the expression of Dkk-1 in endothelial cells, two different cell lines, mouse 
embryonic endothelial progenitor cells (eEPCs) and human umbilical vein endothelial cells 
(HUVECs), were used. eEPCs represent immature endothelial progenitor cells, which have 
retained their ability to proliferate and give rise to functional progeny, whereas HUVECs are 
considered to be differentiated, mature endothelial cells. Both cell types were cultured 
according to standard procedures. For expression analysis, cells were lysed, RNA was 
extracted, purified and used as a template to generate cDNA by reverse transcription. The 
expression of Dkk-1 and ß-catenin was then determined by RT-PCR. For that purpose, RT-PCR 
primers were designed for the mouse and the human Dkk-1 and ß-catenin genes. 
Fig. 4A shows that Dkk-1 is strongly expressed in both eEPCs and HUVECs. The detected 
products from the RT-PCR correspond to the calculated size of 348 bp and 292 bp for the 
mouse and human primer products, respectively. It is further shown in Fig. 4B, that ß-catenin is 
also strongly expressed in eEPCs and HUVECs. The respective primer products of 387 bp and 
312 bp for the mouse and human ß-catenin gene correspond to the estimated sizes. 
The expression of Dkk-1 in eEPCs was dependent on the time cells were kept in culture. As 
demonstrated by Fig. 5, there was an up-regulation of Dkk-1 expression after 24 hrs of culturing 
in comparison to 6 hrs as cells begin to reach confluency.  
If not indicated otherwise, cells were lysed after 24 hrs for molecular analysis.  
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           A 
 
 
          B 
 
Figure 4 (A) Dkk-1 and (B) ß-catenin are strongly expressed in eEPCs and HUVECs. Gene expression  
was determined by RT-PCR analysis.   
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Figure 5 Dkk-1 expression increases in a time-dependent manner in cultured eEPCs. RT-PCR analysis 
of Dkk-1 after 6 and 24 hrs of culturing. Aldolase serves as a positive control to monitor comparable RNA 
amounts and quality among samples.  
 
 
4.2. Expression of Dkk-1 in activated endothelial cells 
It has been shown above, that Dkk-1 is expressed in eEPCs and HUVECs. To investigate a 
possible role of Dkk-1 in neovascularization processes, we used the model of endothelial 
progenitor cell differentiation via cAMP and cell culture under hypoxia as potent angiogenic 
stimuli. Our first model used the special properties that eEPCs show in-vitro. eEPCs, which 
were first isolated and characterized by Hatzopoulos and co-workers (1998), represent 
immature endothelial progenitors retaining their ability to differentiate into more mature cells in 
vitro when stimulated with cAMP plus retinoic acid (RA/cAMP). The differentiation under the 
influence of cAMP represents an activation process that leads to a more typical gene expression 
profile and morphology of endothelial cells (Hatzopoulos et al, 1998).  
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Therefore, we investigated the expression of Dkk-1 in eEPCs activated by RA/cAMP and 
compared the expression levels with untreated eEPCs. The concentrations of the differentiation 
activators all-trans retinoic acid and cAMP (dibutyryl cAMP) were 1 µM and 0.5 mM, 
respectively, and the incubation time was 4 days. Fig. 6 shows the RT-PCR results for Dkk-1. It 
can be seen that Dkk-1 was strongly down-regulated in activated eEPCs. RT-PCR analysis of 
the house-keeping gene Aldolase, which was used as a control, did not change upon stimulation 
by RA/cAMP. 
 
Figure 6 Treatment with RA/cAMP leads to eEPC activation and differentiation. Upon activation of  
eEPCs by RA/cAMP Dkk-1 is down-regulated. RT-PCR analysis of Dkk-1 in activated embryonic endothelial  
cells and untreated controls. Aldolase was used as a control. 
 
Our second model used hypoxia as a strong angiogenic stimulus in eEPCs and HUVECs.  
Hypoxic conditions were induced as described previously (Wei et al., 2004) by incubating 
eEPCs and HUVECs in normal medium for 6 and 24 hrs in 2% O2. eEPCs are known to 
participate in tumor neovascularization in hypoxic metastases, which is accompanied by an 
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increase of VEGF expression in recruited eEPCs and tumor cells (Wei et al., 2004). In the 
following experiments, cDNA of eEPCs, that had been exposed to hypoxia for 6 and 24 hrs 
were used for analysis of Dkk-1 expression. eEPCs that had been cultured under normoxic 
(21% O2) conditions for the same periods of time were used for comparison. Fig. 7 
demonstrates that the expression of Dkk-1 is down-regulated after 6 hrs and is completely 
suppressed after 24 hrs of hypoxia. Similar results were obtained in two other independent 
experiments. To verify that eEPCs were indeed activated by hypoxia, the expression of VEGF 
was investigated under the same conditions by RT-PCR analysis. As expected, Fig. 7 shows an 
up-regulation of VEGF expression in eEPCs submitted to hypoxia. As a control, the expression 
of the house-keeping gene Aldolase was determined, and Fig. 7 shows that the expression of 
Aldolase remained unchanged under hypoxic conditions.     
 
Figure 7 Dkk-1 expression is down-regulated by hypoxia in eEPCs. 
RT-PCR analysis of Dkk-1 expression in eEPCs submitted to hypoxia for 6 hrs and 24 hrs respectively. VEGF was 
used as a positive control, Aldolase as a quality control.  
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Similar experiments as described above for eEPCs were carried out in HUVECs, which in 
contrast to eEPCs represent a fully mature endothelial cell line. In order to follow the time 
course of hypoxia-induced activation more closely, the expression of DKK-1 and VEGF was 
determined after 2, 6, 18, 24 and 36 hrs. HUVECs that were cultured for the same periods of 
time under normoxic conditions served as controls. After the times indicated, non-activated and 
activated HUVECs were lysed, RNA was extracted and transcribed into cDNA by reverse 
transcription for RT-PCR analysis.  
As shown before with eEPCs, up-regulation of VEGF in HUVECs confirmed the hypoxia-
induced activation of this cell line (Fig.8). It is further shown in Fig.8, that the expression of 
DKK-1 is suppressed by hypoxia, with the strongest inhibitory effect on Dkk-1 expression after 
18 hrs. This finding was confirmed in two other independent experiments. In these experiments, 
GAPDH served as the house-keeping gene, and Fig. 8 illustrates that the respective PCR 
products were not affected by hypoxia. It has been demonstrated by Skurk and coworkers 
(2005) that ß-catenin, a central component of the Wnt signaling pathway, is involved in the 
activation of VEGF expression in HUVECs. We therefore investigated, whether the enhanced 
expression of VEGF by hypoxia was also associated with an augmented ß-catenin expression. 
However, it is shown by the time-dependent RT-PCR analysis in Fig. 8, that there was no 
induction of ß-catenin expression after 2 to 36 hrs of hypoxia.  
In summary, the results show that Dkk-1 is expressed in endothelial cells in-vitro and is down-
regulated in two models of endothelial cell activation.  
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Figure 8 Dkk-1 is down-regulated by hypoxia in HUVECs whereas ß-catenin expression remains  
unchanged. RT-PCR analyis of Dkk-1 and ß-catenin expression in HUVECs stimulated by hypoxia for 2, 6, 18,  
24 and 36 hrs. VEGF served as a positive control, GAPDH was used as a quality control.  
 
 
4.3. Cloning of the Dkk-1 CMV construct 
The results of Figs. 7 and 8 demonstrate that Dkk-1 and VEGF show a reciprocal expression 
pattern upon activation by hypoxia. This prompted us to investigate whether DKK-1 
overexpression had an effect on VEGF expression and other components of the Wnt signaling 
pathway in endothelial cells.  
To overexpress DKK-1, the gene was cloned into an expression vector carrying the strong CMV 
enhancer/promoter transcriptional elements. Cloning primers were designed that included the 
whole protein coding sequence of DKK-1 (DKK-1 full length). A forward primer was chosen 
that included the start codon and a reverse primer that included the stop codon. In Fig. 9 the 
whole DKK-1 sequence is shown. Forward primer, reverse primer, start codon and stop codon 
are highlighted.  
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        Human Dickkopf-1 
        1 ggccattacc aatcgcgaaa ccccgcaggg ggctcccgga ccctgactct gcagccgaac 
       61 cggcacggtt tcctggggac ccaggcttgc aaagtgacgg tcattttctc cttctttctc 
      121 cctcttgagt ccttctgaga tgatggctct gggcgcagcg ggagctaccc gggtctttgt 
      181 cgcgatggta gcggcggctc tcggcggcca ccctctgctg ggagtgagcg ccaccttgaa 
      241 ctcggttctc aattccaacg ctatcaagaa cctgccccca ccgctgggcg gcgctgcggg 
      301 gcacccaggc tctgcagtca gcgccgcgcc gggaatcctg tacccgggcg ggaataagta 
      361 ccagaccatt gacaactacc agccgtaccc gtgcgcagag gacgaggagt gcggcactga 
      421 tgagtactgc gctagtccca cccgcggagg ggacgcgggc gtgcaaatct gtctcgcctg 
      481 caggaagcgc cgaaaacgct gcatgcgtca cgctatgtgc tgccccggga attactgcaa 
      541 aaatggaata tgtgtgtctt ctgatcaaaa tcatttccga ggagaaattg aggaaaccat 
      601 cactgaaagc tttggtaatg atcatagcac cttggatggg tattccagaa gaaccacctt 
      661 gtcttcaaaa atgtatcaca ccaaaggaca agaaggttct gtttgtctcc ggtcatcaga 
      721 ctgtgcctca ggattgtgtt gtgctagaca cttctggtcc aagatctgta aacctgtcct 
      781 gaaagaaggt caagtgtgta ccaagcatag gagaaaaggc tctcatggac tagaaatatt 
      841 ccagcgttgt tactgtggag aaggtctgtc ttgccggata cagaaagatc accatcaagc 
      901 cagtaattct tctaggcttc acacttgtca gagacactaa accagctatc caaatgcagt 
      961 gaactccttt tatataatag atgctatgaa aaccttttat gaccttcatc aactcaatcc 
     1021 taaggatata caagttctgt ggtttcagtt aagcattcca ataacacctt ccaaaaacct 
     1081 ggagtgtaag agctttgttt ctttatggaa ctcccctgtg attgcagtaa attactgtat 
     1141 tgtaaattct cagtgtggca cttacctgta aatgcaatga aacttttaat tatttttcta 
     1201 aaggtgctgc actgcctatt tttcctcttg ttatgtaaat ttttgtacac attgattgtt 
     1261 atcttgactg acaaatattc tatattgaac tgaagtaaat catttcagct tatagttctt 
     1321 aaaagcataa ccctttaccc catttaattc tagagtctag aacgcaagga tctcttggaa 
     1381 tgacaaatga taggtaccta aaatgtaaca tgaaaatact agcttatttt ctgaaatgta 
     1441 ctatcttaat gcttaaatta tatttccctt taggctgtga tagtttttga aataaaattt 
     1501 aacatttaat atcatgaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 
 
Figure 9 Gene sequence of the human DKK-1 gene (Acc. No. AF 127563; www.ncbi.nlm.nih.gov).  
Start and stop codon are highlighted in red. Forward and reverse primers include the start and the stop codon,  
respectively, to be able to clone the whole protein coding sequence of DKK-1 (DKK-1 full length) into the  
plasmid vector. Primers are highlighted in grey.   
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To ligate the DKK-1 gene product into the expression vector, the restriction sites for BamHI 
and EcoRI were added to the forward and reverse primers, respectively. The primers were then 
synthesized by MWG. After synthesis, the cloning primers were tested using cDNA prepared 
from HUVEC RNA. Fig. 10 shows the electrophoresis gel of the primer product which 
corresponds to the calculated product size of 796 bp.   
 
 
Figure 10 RT-PCR using the DKK-1 cloning primers in HUVECs. The PCR product (DKK-1 full  
length) matches the calculated product size of 796 bp.  
 
 
Following amplification, several PCRs containing the DKK-1 full length product were pooled 
to increase the amount of DNA. This pooled DNA was purified, digested with the appropriate 
restriction enzymes (BamHI and EcoRI) and finally ligated into the CMV-expression vector 
(pBK-CMV, Stratagene). The ligation product was transformed into competent E. coli. The 
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transformed bacteria were transferred to LB-medium and amplified on culture plates containing 
kanamycin for selection. After Mini plasmid DNA preparation, plasmids were digested with 
EcoRI and BamHI and gel-electrophoresis was carried out. In two of eight clones from the 
Mini-preparation, the DKK-1 insert could be detected with the correct size of 796 bp. From the 
Mini-preparation cultures that contained the correct inserts, Maxi- preparations were carried out 
to increase the yield of DNA. Commercial sequencing (Sequiserve, Vaterstetten) confirmed the 
correct sequence for DKK-1 in the pBK-CMV-vector. Fig. 11 shows the DKK-1 construct 
(pBK-CMV-DKK-1). 
 
 
 
Figure 11 DKK-1 construct (pBk-CMV-DKK1) 
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4.4. Influence of DKK-1 overexpression in HUVECs on VEGF and components of 
Wnt signaling 
HUVECs were transfected with the pBK-CMV-DKK-1 expression vector and the expression of 
VEGF (a target gene of Wnt signaling) and important components of the Wnt signaling 
pathway such as LRP6, ß-catenin and DVL was investigated. 
To transfect HUVECs with the pBK-CMV-DKK-1 construct, three plates of HUVECs in 
culture (passage 4, 80-90% confluency) were prepared. One plate was left untransfected and the 
second was transfected with an empty pBK-CMV-vector as control. HUVECs on the third plate 
were transfected with 8µg/µl DNA of the pBK-CMV-DKK-1 construct. Transfection was 
carried out with lipofectamine. After 3hrs, the transfection was stopped by adding fresh 
medium. The cells were left overnight in culture and were lysed 24 hrs after stopping the 
transfection. Using an RNA isolation kit (Qiagen), the RNA was extracted from the cells and 
reversely transcribed into cDNA for RT-PCR analysis. As shown in Fig. 12, transfection with 
the DKK1-CMV-construct increased DKK-1 expression in comparison to the control 
transfection with the empty pBK-CMV-vector. It is further shown, that overexpression of Dkk-1 
had no effect on the expression of the Wnt co-receptor LRP6 and the central component of the 
Wnt signalling pathway ß-catenin. There was also no effect on the expression of DVL (data not 
shown). The expression of VEGF however was strongly inhibited in the DKK-1 overexpressing 
cells. These results were confirmed in two further independent experiments. In addition, Fig. 12 
shows that the expression of the house-keeping gene Aldolase, which served as a control, was 
not affected in the DKK-1 overexpressing cells. 
Taken together, the results demonstrate that DKK-1 overexpression directly decreased VEGF 
expression, but had no influence on the RNA expression of the analysed Wnt signaling pathway 
components.   
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Figure 12 DKK-1 overexpression down-regulates VEGF expression in HUVECs, whereas components of the 
Wnt signaling pathway such as LRP6 and ß-catenin remain unchanged. RT-PCR analysis using gene specific 
primers reveals that that DKK-1 expression is increased by transfection of the pBK-CMV-DKK-1 construct in 
comparison to the controls that were untransfected or transfected with an empty vector. Aldolase was used as a 
control.  
 
 
4.5. Expression of Dkk-1 and ß-catenin in vessels and adult mouse tissues in-
vivo  
In a next step, we investigated, whether Dkk-1 was also expressed in vessels in vivo. For that 
purpose, the thoracic and abdominal aorta, the carotid artery and the iliac arteries were isolated 
from mice and pooled. From these arteries, RNA was transcribed into cDNA for RT-PCR 
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analysis. As shown in Fig. 13, there was strong expression of the Dkk-1 gene in these blood 
vessels. Aldolase was used as a control.  
 
 
Figure 13 Dkk-1 is strongly expressed in mouse arteries. RT-PCR analysis of Dkk-1 using RNA isolated from 
big mouse arteries (aorta, iliac arteries and carotid arteries) that were pooled before RNA extraction was 
performed. Results are shown for three independent animals. Aldolase serves as a control.  
 
 
Since Dkk-1 was expressed in endothelial cells in-vitro, we investigated the localization of Dkk-
1 in the mouse aorta. Sections of mouse aorta were prepared and stained with an antibody 
directed against Dkk-1. Fig. 14 shows that the corresponding immunofluorescence signal for 
Dkk-1 is located predominantly in the endothelial layer of the aorta (Fig. 14A). To further 
validate the endothelial localization, we performed double staining for Dkk-1 with the 
endothelial marker platelet endothelial cell adhesion molecule-1 (PECAM-1). The results in 
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Fig. 14B confirm that Dkk-1 and PECAM-1 co-localize in the endothelium. It is further shown 
that Dkk-1 expression is predominant in the endothelium and only weakly expressed in the 
smooth muscle layer of the aorta. 
 
 
Figure 14 Dkk-1 is expressed in the endothelium in vivo.  
Immunofluorescence staining of mouse aorta (magnification 20x). (A) Dkk-1 is predominantly found in the 
endothelium. (B) Co-staining with the endothelial marker PECAM-1 (CD 31, in green) confirms a predominant  
endothelial expression of Dkk-1 (red color).  
 
  
In order to assess the expression of ß-catenin in blood vessels, mouse heart tissue sections from 
the left ventricle were stained with an antibody directed against ß-catenin. Fig. 15 shows the 
corresponding immunofluorescence signal from a coronary artery of the epicardium, indicating 
that ß-catenin expression is evenly distributed across the coronary vessel wall. Note that the 
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neighbouring coronary vein shows no ß-catenin staining. In addition to the expression in 
coronary vessels, ß-catenin is found in intercalated discs throughout the myocardium (Fig.15 
insert). 
 
 
Figure 15 ß-catenin is expressed in coronary vessels of the myocardium. Immunofluorescence staining of  
the mouse myocardium (magnification 20x). The picture was taken of the epicardial area of the left ventricle  
showing a coronary artery and a coronary vein. Immunofluorescence staining against ß-catenin shows that 
expression is predominantly found in the smooth muscle layer. Additionally, ß-catenin is found in the intercalated 
discs of the myocardium (top left insert).  
 
 
To evaluate the distribution of Dkk-1 and ß-catenin in adult tissues, we analyzed different 
mouse tissues by RT-PCR. For that purpose, RNA isolated from various mouse organs was 
transcribed into cDNA. Fig. 16 shows that Dkk-1 is expressed in distinct tissues with a 
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comparatively stronger expression in adipose tissue and skeletal muscle. There was also a 
positive signal in mouse brain. ß-catenin is equally expressed in all mouse organs tested 
showing only a weaker expression in spleen tissue. ß-actin was used as a control. 
 
Figure 16 Dkk-1 and ß-catenin are expressed in adult mouse tissues. RT-PCR analysis of Dkk-1 and  
ß-catenin expression in various adult mouse organs. Dkk-1 is weakly expressed in all organs tested except for  
lung tissue with comparatively stronger expression in adipose tissue and skeletal muscle. ß-catenin is equally 
expressed in all organs with comparatively weaker expression in spleen tissue. ß-actin served as control.  
 
 
4.6. Expression of Dkk-1 and ß-catenin in normal and ischemic mouse brain 
The in-vitro experiments have shown that Dkk-1 is down-regulated in endothelial cells 
submitted to hypoxia. This effect is accompanied by an increase in VEGF but no change in ß-
catenin expression. We have further shown that in-vivo Dkk-1 and ß-catenin are expressed in 
big arteries of the mouse (Fig. 13-15) and in various adult mouse tissues, including mouse brain 
(Fig. 16). In a next step we used a mouse model of stroke to evaluate a possible role of Dkk-1 
and ß-catenin in vivo in brain ischemia/hypoxia. Expression patterns of Dkk-1 and ß-catenin in 
the infarcted area were directly compared to the unaffected contralateral hemisphere.  
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Frontal sections of the mouse brain were prepared and stained with antibodies directed against 
Dkk-1. Fig. 17 shows sections of the cortex (A), the hippocampus (B) and the subcortical areas 
of the mouse brain (C-E). To our surprise, we found that in these areas Dkk-1 was specifically 
expressed in neurons but not in blood vessels. Double-staining with the specific neuronal 
marker neuron specific nuclear protein (NeuN) shows that the signals for Dkk-1 and NeuN co-
localize (D). To further specify the neuronal expression of Dkk-1, co-staining of Dkk-1 and a 
marker for astrocytes glial fibrillary acidic protein (GFAP) was performed. As can be seen in 
Fig. 17 E, there was no co-localization of Dkk-1 and GFAP, indicating that astrocytes and 
probably other glial cells do not express Dkk-1.  
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Figure 17 Dkk-1 is expressed in neurons of the mouse brain.  
Immunofluorescence staining against Dkk-1 on frontal sections of mouse wild-type brains (magnification 20x). 
(A) Dkk-1 is expressed in neurons of the cortex, (B) the hippocampus and (C, D) subcortical areas.  
(D) Co-staining with the neuronal marker NeuN shows co-localization of NeuN (green) and Dkk-1 signals (red 
color). (E) Dkk-1 (red color) and GFAP (green) co-staining shows that Dkk-1 is not expressed in astrocytes.  
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In another set of experiments, ß-catenin expression in normal wildtype brain tissue was 
evaluated. Directing special attention to the vessels, frontal sections of the brain hemispheres 
were viewed after immunofluorescence staining with ß-catenin antibodies. In contrast to Dkk-1, 
ß-catenin was expressed in medium-sized vessels of the brain, but not in neurons or glial cells 
(Fig. 18).  
 
 
Figure 18 ß-catenin is expressed in vessels of the brain. 
Immunofluorescence staining against ß-catenin in sections of wild-type mouse brain. Arrow heads indicate   
ß-catenin staining of medium-size brain vessels.  
 
 
In order to evaluate the influence of ischemia/hypoxia on Dkk-1 and ß-catenin expression, we 
used brains from mice that had been subjected to ischemic stroke by middle cerebral artery 
occlusion (MCAO) for 60 minutes. Thereafter, occlusion was released and the animals were 
killed 24 or 48 hrs later. The brains of the mice were isolated and frontal sections of the brain 
were stained with antibodies directed against Dkk-1. Fig. 19A shows the border of the infarcted 
area 24 hrs after stroke and it can be seen that Dkk-1 expression is down-regulated in the 
neurons of the infarct area. As expected, the demarcation area of the ischemic stroke is 
characterized by the astrocytic wall depicted in Fig 19B by the green GFAP staining. As in 
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normal brains, the Dkk-1 antibody specifically stained neurons and there was no indication of 
blood vessel staining. The same pattern of neuronal Dkk-1 expression as described above was 
also observed 48 hrs after stroke (not shown).  
 
 
Figure 19 Dkk-1 expression in neurons decreases in the area of infarction.  
Immunoflorescence staining against Dkk-1 in sections of mouse brain 24 hrs after MCAO (magnification 20x). 
The parts shown on the pictures are taken from the border zone of the infarct. (A) On the side of the infarct,  
Dkk-1 staining is diminished. (B) Dkk-1 expression (red color) stays restricted to neurons, revealed by the co- 
staining with the astrocyte marker GFAP.  
 
 
In a further set of experiments, the expression of ß-catenin as a central component of the Wnt 
signaling pathway was analyzed in the mouse brain 48 hrs after ischemic stroke. Again, frontal 
sections of the mouse brain were examined. The expression of ß-catenin in the non-infarcted 
contralateral hemisphere was restricted to blood vessels (Fig. 20A). Double staining with the 
smooth muscle marker α-smooth muscle actin (α -SM) revealed that ß-catenin was located in 
the smooth muscle layer (media) of these vessels (Fig. 20B). Double staining with ß-catenin 
and the endothelial marker PECAM-1 showed no co-localization, indicating that ß-catenin 
expression in the contralateral hemisphere is restricted to the smooth muscle layer (Fig. 20C).  
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In contrast to the unaffected hemisphere, there was a shift in the expression pattern of ß-catenin 
in the infarct area 48 hrs after induction of stroke. Fig. 20D shows blood vessels in the infarcted 
area which are positive for ß-catenin. Arrows indicate examples of these vessels. To elucidate 
the localization of ß-catenin staining, we performed co-staining with the endothelial marker 
PECAM-1. Fig. 20E demonstrates the co-localization of ß-catenin and PECAM-1 indicating an 
endothelial localization of ß-catenin in brain blood vessels after infarction.   
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Figure 20 ß-catenin expression shifts from a predominant smooth muscle expression in the contralateral  
hemisphere to an endothelial expression in the border zone of the infarction 48 hrs after MCAO. 
Immunofluorescence staining against ß-catenin in sections of mouse brain 48 hrs after MCAO (magnification  
20x). (A) The contralateral hemisphere is not affected by the infarct. ß-catenin is expressed in medium-sized  
vessels. (B) Co-stainings with the smooth muscle marker α-actin (red color) and (C) the endothelial marker 
PECAM-1 (CD 31) (red color) show that ß-catenin expression locates to the smooth muscle layer of these 
vessels (B) and not to the endothelium (C). (D) In the border zone of the infarction, ß-catenin is found to be  
expressed in small vessels (magnification 40x). (E) Co-staining of ß-catenin (green color) and the endothelial 
marker PECAM-1 (CD 31 red). Orange color due to staining overlap reveals that ß-catenin expression has changed 
to an endothelial expression pattern.   
  
 
Taken together, the in-vivo experiments demonstrate that 1) Dkk-1 is expressed in the great 
peripheral arteries but not in brain vessels. 2) Dkk-1 expression in brain is restricted to neurons 
and decreases in the infarcted area. 3) ß-catenin expression shifts from a predominant 
localization in the media of brain vessels to endothelial cell expression in the infarcted area.  
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5. Discussion 
5.1. Expression of Dkk-1 and ß-catenin in endothelial cells in-vitro 
During the last years, reports from various investigators have shown that several components of 
the Wnt signaling pathway are expressed in vascular cells. Functional analysis of some of these 
factors suggests that active Wnt signaling via ß-catenin plays an important role in vessel 
formation and remodeling. Wnt antagonism, on the other hand, exerted by a large variety of 
secreted extracellular antagonists such as WIF, sFRPs and Dkks, is thought to be associated 
with vessel stability (Goodwin & D´Amore, 2002).   
In HUVECs, expression of components of the Wnt signaling pathway such as members of the 
Wnt, Fz, Tcf and Lef gene families have been detected (Wright et al., 1999; Masckauchan et al., 
2005). There is an increasing body of evidence that the canonical Wnt signaling pathway 
through ß-catenin is involved in angiogenesis by promoting endothelial proliferation, migration 
and survival (for HUVECs see: Masckauchan et al., 2005; Skurk et al., 2005; Kim et al., 2006). 
Promotion of angiogenesis by ß-catenin in HUVECs, as assessed by transduction of HUVECs 
with ß-catenin, might be mediated in part through the transcriptional activation of VEGF (Skurk 
et al., 2005). 
In contrast, only little is known about the expression and function of secreted Wnt antagonists 
in endothelial cells. In HUVECs, FrzA/sFRP1, a member of the sFRP family, was shown to 
exert an anti-proliferative effect (Ezan et al., 2004). The same observation could be made for 
Dkk-1 in the tumor cell line NIH3T3 (Fedi et al., 1999). Our finding that Dkk-1 is strongly 
expressed in HUVECs shows that another potent secreted Wnt antagonist is present in mature 
endothelial cells pointing to more complex regulation of the Wnt signaling pathway in 
endothelial cells.  
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Wnt signaling is commonly observed during embryogenesis. In vascular development, a role 
for Wnt/ß-catenin signaling has also been implicated (Goodwin & D´Amore, 2002). For 
example, in mouse development, Wnt5a, Wnt10b and Fz5 are expressed in vascular endothelial 
cells of blood vessels in the embryonic yolk sac. It has been assumed that Wnt5a and Wnt10b 
are ligands in Fz5-dependent angiogenesis in the yolk sac (Ishikawa et al., 2001). Wnt2 
deficient mice show an abnormal placental vasculature (Monkley et al., 1996) and ß-catenin 
expression is regulated during vascular development and degeneration in avian mesonephros, a 
model for vascular development (Nacher et al., 2005). Another study shows that conditional 
inactivation of ß-catenin in endothelial cells of mouse embryos results in alterations in vascular 
patterning and increased vessel fragility (Cattelino et al., 2003). In the present study we show 
that ß-catenin, the central component of the canonical Wnt signaling pathway, is expressed in 
embryonic endothelial progenitors participating in early vasculogenesis. Interestingly, Wnt 
antagonists such as Dkk-1 and FrzA/sFRP1 also seem to be involved in vascular development. 
It was shown that Dkk-1 and FrzA/sFRP1 were temporarily expressed in the aorta during 
mouse embryogenesis (Monaghan et al., 1999) and during embryonic vascular development in 
the inner lining of the endothelial cell layer of the visceral yolk sac, respectively (Jaspard et al., 
2000).  
Our results demonstrate that the Wnt antagonist Dkk-1 is expressed in eEPCs, which represent 
immature endothelial progenitors from mice that are involved in early vascular development. 
These cells show the special characteristics of immature endothelial precursors and express 
endothelial cell specific markers such as Thrombomodulin and Tie-2 (Hatzopoulos et al., 1998).  
Wnt/ß-catenin signaling in vascular development is of special interest because many of the 
signals relevant to blood vessel development are reactivated during adult blood vessel 
formation (Ferguson et al., 2005). 
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5.2. Expression of Dkk-1 in activated endothelial cells 
In vascular development, angiogenesis and vasculogenesis contribute to the formation of the 
vasculature. Differentiation and maturation of endothelial precursors is one of the crucial steps 
in the formation of a functional endothelium (Ferguson et al., 2005; Jain, 2003; Carmeliet, 
2003). In vitro, eEPCs have the ability to differentiate when the cells are treated with 
RA/cAMP. Stimulation of eEPCs with RA/cAMP leads to the induction of a set of genes 
specific to the endothelial lineage (e.g. Flk-1, vWF, P-selectin, M-CSF) proving a new model to 
study the transition of immature endothelial cells to a mature endothelium. This model is highly 
valuable to identify genes regulated in endothelial differentiation and helps to understand the 
molecular mechanisms underlying endothelial development (Hatzopoulos et al., 1998). In this 
study, we show that upon differentiation of eEPCs with RA/cAMP Dkk-1 is down-regulated 
indicating a function in endothelial differentiation. It is interesting to note that Wnt signaling 
has been implicated in the differentiation of the vasculature. ß-catenin has been shown to 
increase endothelial cell differentiation (Skurk et al., 2005), which is consistent with our 
findings that Dkk-1 expression decreased upon differentiation possibly to allow active Wnt 
signaling via ß-catenin. A recent report shows that during in-vitro differentiation of embryonic 
stem cells (ES) various members of the Wnt signaling pathway, among them Dkk-1, are 
differentially regulated. It is demonstrated that Wnt signaling activity is likely to promote 
endothelial cell differentiation (Wang et al., 2006).  
Our findings that Dkk-1 is down-regulated upon endothelial differentiation with RA/cAMP has 
also interesting implications for a role of Dkk-1 in angiogenesis since as mentioned above 
signaling during embryonic vascular development is recapitulated in adult vessel formation 
(Ferguson et al., 2005). Moreover, treatment of eEPCs with cAMP represents an activation 
process which is displayed in activation and inhibition of a variety of genes (Vajkoczy et al., 
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2003). This activation of endothelial cells is also observed during the early stages of 
angiogenesis when quiescent endothelial cells are stimulated by pro-angiogenic factors.  
In another model of endothelial activation, we investigated the effect of hypoxia on Dkk-1 
expression. Hypoxia is an important stimulus for angiogenesis and EPCs that contribute to 
postnatal vasculogenesis (Carmeliet, 2003; Asahara et al., 1999; Takahashi et al., 1999). It is 
known from previous studies that eEPCs when used in animal models in vivo respond to 
hypoxia since they could be shown to home preferentially to hypoxic lung metastases that have 
a low vessel density. In vitro, eEPCs are activated by hypoxia and respond with an increase in 
VEGF expression (Wei et al., 2004). In another model of hypoxia eEPCs were shown to 
enhance vascularization and tissue recovery in acute and chronic ischemia (Kupatt et al., 2005). 
Similar to eEPCs, HUVECs also respond to hypoxia with an increased VEGF expression in 
vitro (Namiki et al., 1995). Our results confirm these data, eEPCs as well as HUVECs increased 
their VEGF expression when challenged with hypoxia. At the same time a down-regulation of 
Dkk-1 expression was observed in both cell types.  
ß-catenin is known to promote proliferation and angiogenesis in HUVECs. This pro-angiogenic 
effect is thought to be meditated in part through the induction of VEGF by ß-catenin (Skurk et 
al., 2005; Kim et al., 2006). Our experiments with HUVECs showed, however, that ß-catenin 
does not respond to hypoxia, at least at the RNA level. Although transcriptional regulation of ß-
catenin, measured in our experiments by RT-PCR, was not observed during hypoxia, this does 
not exclude that hypoxia leads to stabilization accumulation of cytosolic ß-catenin protein, 
which subsequently can interact with Lef/Tcf transcription factors contributing to specific gene 
expression such as VEGF. 
Wnt antagonists like Dkk-1 and FrzA/sFRP1 are secreted proteins which are thought to 
promote vessel stability (quiescence) and expression of these antagonists may decrease in 
angiogenic conditions in order to allow active Wnt signaling. FrzA/sFRP1 is expressed in 
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quiescent bovine aortic endothelial cells (BAECs) in vitro and in vivo and inhibits proliferation 
of BAECs when these cells were transiently transfected with a plasmid coding FrzA/sFRP1 or 
when the purified FrzA/sFRP1 protein was added to the cells (Dupláa et al., 1999). This 
antiproliferative effect is probably due to an inhibition of the Wnt/ß-catenin pathway (Ezan et 
al., 2004). In addition, Dupláa and coworkers (1999) showed that BAECs expressed barely 
detectable levels of FrzA/sFRP1 when the cells were sparse and proliferating, but high 
expression levels when the cells were grown to confluency.  
In line with these observations, we find that eEPCs 6 hrs after plating express low levels of 
Dkk-1, which strongly increase after 24 hrs of culturing. This finding can be explained by 
assuming that passaging and exchange of medium represents an activation mechanism, which 
causes the cells to proliferate and therefore to inhibit the transcription of Dkk-1. When eEPCs 
are confluent 24 hrs later and the proliferation stimulus has decreased, Dkk-1 expression is 
enhanced. 
 
5.3. Influence of Dkk-1 overexpression in HUVECs on VEGF and components of 
Wnt signaling 
Our experiments with HUVECs challenged with hypoxia showed that Dkk-1 and VEGF 
expression was regulated in opposite directions, whereas ß-catenin expression remained 
unchanged. Since VEGF and ß-catenin are important pro-angiogenic factors we investigated 
whether DKK-1 had a direct influence on the expression of VEGF and ß-catenin.  
To accomplish this goal, we prepared a plasmid coding DKK-1 for gain-of-function 
experiments. A pBK-CMV phagemid vector (Stratagene) carrying the powerful CMV 
enhancer/promoter was chosen to allow sufficient overexpression of DKK-1, which was cloned 
into the multiple cloning site of the vector (MCS). As expected, transfection of HUVECs with 
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the pBK-CMV-DKK-1construct resulted in an increased DKK-1 expression at the RNA level. 
Unfortunately, our attempts to detect DKK-1 in transfected HUVECs on the protein level by 
Western Blot analysis failed. However, when we repeated the transfection experiment in 
eEPCs, Western Blot analysis was successful and revealed an enhanced DKK-1 expression on 
the protein level (data not shown).  
In HUVECs, transduction of ß-catenin was shown to induce VEGF expression (Skurk et al., 
2005). In line with that observation, we found that HUVECs overexpressing the Wnt antagonist 
DKK-1 expressed lower level of VEGF. In BAECs, however, Dufourcq and co-workers (2002) 
could not find a difference in VEGF expression when the cells were treated with the Wnt 
antagonist FrzA/sFRP1. In contrast to the down-regulation of VEGF, DKK-1 overexpression in 
HUVECs had neither an influence on the expression of ß-catenin nor on other components of 
the Wnt signaling pathway such as LRP6 or DVL. This finding points to a specific regulation of 
VEGF by DKK-1 in HUVECs.  
To further validate our results more experiments are needed, in particular it should investigated 
whether the changes in VEGF expression can be confirmed on the protein level and VEGF 
expression can be increased by interfering with DKK-1 through RNAi experiments. 
 
5.4. Expression of Dkk-1 and ß-catenin in vessels and adult mouse tissues in-
vivo  
In a study identifying genes involved in the induction and maintenance of the quiescent, 
differentiated phenotype of vascular endothelium, the Wnt antagonist FrzA/sFRP1 was found to 
be highly expressed in the endothelium of adult bovine aorta (Dupláa et al., 1999). Similar 
results are presented in the present study by demonstrating a high expression level of Dkk-1 in 
large peripheral arteries and in the endothelium of mouse aorta. It should be emphasized that 
 74
  DISCUSSION 
the endothelium of the aorta is quiescent, highly polarized and nonproliferating. As has been 
shown by our in vitro experiments, this is a condition associated with a high expression of Dkk-
1.  
In contrast, ß-catenin has been shown to be involved in endothelial cell proliferation. 
Accumulation of cytosolic and nuclear ß-catenin was observed in proliferating vessels of 
different tumors of the central nervous system (Yano et al., 2000a; Yano et al., 2000b; Eberhart 
et al., 2000). ß-catenin has also been described in neovascularization processes after myocardial 
infarction and overexpression of ß-catenin enhanced angiogenesis in a model of hind limb 
ischemia in mice (Blankesteijn et al., 2000; Kim et al., 2006). It has been observed that in the 
adult vasculature ß-catenin is rarely accumulated in the cytoplasm or the nucleus (Goodwin & 
D´Amore, 2002). In line with these findings, we observed no particular endothelial expression 
of ß-catenin in larger arteries (and veins) of the myocardium, but a predominant smooth muscle 
cell expression.  
Wnt signaling is one of the main regulatory signaling pathways that plays a role in the 
development and maintenance of organ systems. Our findings that Dkk-1 and ß-catenin are 
expressed in various mouse organs underscore this importance of Wnt signaling. Although Dkk-
1 is only weakly expressed in most tissues, this finding presents new results concerning the 
tissue distribution of Dkk-1 in adult mice since in previous studies Dkk-1 was only detected in 
placenta tissue and the eye (Krupnik et al., 1999; Monaghan et al., 1999). 
 
5.5. Expression of Dkk-1 and ß-catenin in normal and ischemic mouse brain 
In the present study, we found that Dkk-1 was down-regulated upon hypoxia in endothelial cells 
in vitro. In vivo, Dkk-1 was expressed in large arteries of the mouse. These observations 
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prompted us to investigate whether in an animal model of tissue hypoxia Dkk-1 was also down-
regulated in vessels.  
To our surprise, we could not detect Dkk-1 in vessels of the mouse brain as in the aorta. 
Instead, we found a highly specific neuronal expression of Dkk-1 as validated by co-staining 
brain sections with the neuronal marker NeuN or the astrocyte marker GFAP. Our observations 
are in line with the findings of Krupnik et al. (1999) for Dkk-3, another member of the Dkk 
family. Dkk-3 was found to be expressed in neurons of the cortex and the hippocampus by in 
situ hybridization in adult mice. Using Dkk-1 knockout mice it could be demonstrated that 
Dkk-1 is necessary for the patterning of the forebrain and for the induction of head formation in 
Xenopus laevis (Mukhopadhyay et al., 2001; Glinka et al., 1998). In contrast to our 
observations, a recent report shows that in brains of patients suffering from Alzheimer´s disease 
Dkk-1 immunostaining is observed in the temporal cortex and white matter whereas age-
matched controls show no Dkk-1 expression (Caricasole et al., 2004). A more recent study from 
the same group demonstrates that Dkk-1 was induced in the hippocampus of gerbils and rats 
subjected to a transient global ischemia as well as in cultured cortical neurons challenged with 
the excitatory amino acid N-methyl-D-aspartate (NMDA) as an in vitro model of excitotoxic 
neuronal death (Cappucio et al., 2005). In gerbils, no immunostaining for Dkk-1 could be 
observed in the hippocampus of controls whereas in control rats a low expression of Dkk-1 
could be observed. It should be noted, however, that Cappucio at al. (2005) show an increased 
Dkk-1 expression in ischemic gerbil brains in non-neuronal cells and blood vessels in defined 
areas (CA1 and CA3 regions) of the hippocampus. In contrast to these observations, we found 
no indication of Dkk-1 expression in mouse brain vessels neither in wild-type animals nor in 
ischemic animals subjected to focal ischemia by MCAO. Our findings, however, indicate that 
Dkk-1 is not only expressed in neurons of the hippocampus but also in neurons of the cortex 
and subcortical areas of wild-type mice independent of hypoxia. Upon hypoxia, we observed an 
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increase in GFAP staining around the infarct which is in accordance with previous reports 
showing an astrocytic reaction to brain ischemia (Chen et al., 1993; Clark et al., 1993). 
Astrocyte functions are known to influence neuronal survival including glutamate uptake, 
glutamate release, free radical scavenging, water transport and the production of cytokines and 
nitric oxide (Chen & Swanson, 2003). In contrast to the observations of Cappucio et al. (2005), 
we found a decrease of Dkk-1 expression in neurons in the infarcted area rather than an 
increase. Diminished Dkk-1 expression in the border zone of the infarction co-localized with a 
decreased NeuN staining. This may not necessarily be due to neuronal loss, since NeuN 
immunoreactivity readily decreases after metabolic perturbations although neurons still 
preserve their integrity (Ünal-Çevik et al., 2004). In the core of the infarction, however, no 
staining for either Dkk-1or NeuN was observed (data not shown). The different results of our 
study compared with those of Cappucio and co-workers (2005) may be due to different 
experimental procedures such as global versus focal ischemia. In the case of global ischemia 
vessels were occluded for only a few minutes whereas in our model of focal ischemia MCA 
occlusion lasted for 60 minutes. In addition, tissue specificity may have played a role, since in 
our model of MCAO the hippocampus was not affected and therefore Dkk-1 regulation was not 
expected.  
Our in vitro results have shown that ß-catenin mRNA levels were not regulated upon hypoxia in 
HUVECs. In vivo, however, there is a report demonstrating that ß-catenin is induced by 
hypoxia in a mouse model of hindlimb ischemia (Kim et al., 2006). In another study, ß-catenin 
was found in endothelial cells of newly formed and pre-existing vessels within the infarcted 
area of the rat heart. Outside the infarction area or in sham operated animals there was no 
indication of endothelial staining of ß-catenin, suggesting a role for this Wnt signaling 
component during neovascularization after myocardial infarction (Blankesteijn et al., 2000).  
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In the present study, we used a mouse model of brain ischemia to evaluate the expression and 
regulation of ß-catenin in blood vessels. Similar to the findings of Blankesteijn and co-workers 
(2000), we observed that ß-catenin was expressed by endothelial cells of the border zone of the 
brain infarct 48 hrs after MCAO. This finding represents a shift of ß-catenin expression from a 
predominant vascular smooth muscle cell expression in the unaffected contralateral hemisphere 
to the endothelium in the penumbra.  
It is known from previous reports that 24 hrs after the induction of brain ischemia by MCAO, 
neovascularization starts to appear in rodent stroke models (Marti at al., 2000; Conway et al., 
2003). After 48 hrs, a strong increase of PECAM-1 positive endothelial cells was observed at 
the border zone around the infarcted area. PECAM-1 staining of endothelial cells co-localizes 
with markers of cell proliferation suggesting an angiogenic reaction characterized by 
endothelial cell proliferation and vessel growth (Marti et al., 2000). Our observation that ß-
catenin expression is shifted from smooth muscle expression in the unaffected part of the brain 
to an endothelial expression in the border zone of the infarction may indicate that ß-catenin 
plays an important role in the angiogenic response after ischemic stroke.  
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6. Summary 
Angiogenesis and neovascularization depend on endothelial cell proliferation and migration. 
Active Wnt-signalling through its central component, ß-catenin, is thought to play a role in 
angiogenesis. In recent work, it has been emphasized that ß-catenin plays an important role in 
neovascularization after myocardial infarction, in cell proliferation and cell migration and 
angiogenesis. Another key factor in promoting endothelial cell proliferation, migration and 
angiogenesis is vascular endothelial growth factor (VEGF), which could be shown to be a 
target gene of ß-catenin. In contrast, inhibition of Wnt signalling is thought to be associated 
with vessel stability and vessel regression. Dickkopf-1 (Dkk-1) is a well characterized and 
potent inhibitor of Wnt signaling which is thought to specifically antagonize canonical Wnt 
signaling.  
The aim of the present study was to investigate the expression of Dkk-1 in endothelial cells in 
vivo and in vitro and elucidate its regulation in conditions of endothelial activation. A further 
purpose of the study was to compare expression of Dkk-1 under hypoxic conditions in vitro and 
in vivo with the expression of ß-catenin and investigate a possible influence of Dkk-1 on the 
pro-angiogenic factors ß-catenin and VEGF.  
In the present work, we demonstrated that Dkk-1 is expressed in mouse embryonic endothelial 
progenitor cells (eEPCs) and human umbilical vein endothelial cells (HUVECs) in vitro, which 
represent immature endothelial precursors and fully mature endothelial cells, respectively. We 
found that Dkk-1expression is down-regulated in eEPCs activated by a differentiation stimulus 
(RA/cAMP), by an angiogenic stimulus (hypoxia) or by an endothelial growth stimulus (fresh 
medium). Stimulation of HUVECs with hypoxia confirmed the down-regulation of DKK-1 
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expression under hypoxic conditions. Overexpression of DKK-1 in HUVECs revealed that 
DKK-1 suppressed VEGF expression, but had no influence on ß-catenin expression.  
In vivo, Dkk-1 expression was found in large peripheral arteries and in the endothelium of 
mouse aorta, which represents a quiescent, highly polarized and non-proliferating endothelium, 
but not in vessels of the brain. Instead, our in vivo experiments in mouse brains showed that 
Dkk-1 expression in the brain is restricted to neurons. In an animal model of brain ischemia 
neuronal expression of Dkk-1 decreased in the infarcted area.  
In the present study, we further demonstrated that ß-catenin was also expressed in eEPCs and 
HUVECs. In vitro, stimulation of HUVECs with hypoxia had no effect on ß-catenin expression. 
In vivo, ß-catenin expression could be found in larger arteries of the heart and brain with a 
predominant expression in the smooth muscle layer. In an animal model of brain ischemia, ß-
catenin shifted its expression from a predominant localization in the media of brain vessels in 
the unaffected contralateral hemisphere, to an endothelial cell expression in the infarcted area 
48 hrs after MCAO.  
We conclude that Dkk-1 expression might be associated with the quiescent state of endothelial 
cells compared to the activated state in which Dkk-1 expression is down-regulated. In 
maintaining the quiescent state Dkk-1 might interfere with VEGF expression. An animal model 
of brain ischemia showed that Dkk-1 is probably not involved in neovascularization after brain 
infarction since it is not expressed in small vessels. In contrast, ß-catenin could be found in 
endothelial cells in the border zone of infarction, pointing to a role of ß-catenin in 
neovascularization after brain ischemia.   
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7. Zusammenfassung 
Endothelzellproliferation und -migration sind Komponenten der Angiogenese und 
Neovaskularisation. Aktive Signaltransduktion über den Wnt Signalweg und dessen zentrale 
Komponente ß-catenin wird mit Angiogenese in Verbindung gebracht. In neueren Arbeiten 
konnte gezeigt werden, dass ß-catenin eine wichtige Rolle in der Neovaskularisation nach 
einem Myokardinfarkt, in der Zellproliferation, der Zellmigration und der Angiogenese spielt. 
Eine weitere wichtige Schlüsselkomponente bei der Vermittlung von endothelialer 
Zellproliferation und -migration ist der Vascular endothelial growth factor (VEGF), von dem 
gezeigt werden konnte, daß er ein Target Gen von ß-catenin ist. Im Gegensatz dazu ist eine 
Inhibition des Wnt Signalweges mit dem Erhalt von Gefäßen und Gefäßregression assoziiert. 
Dickkopf-1 (Dkk-1) ist ein gut charakterisierter und potenter Inhibitor der Wnt 
Signaltransduktion, von dem angenommen wird, das er ein spezifischer Inhibitor des 
kanonischen Wnt Signalweges ist.  
Das Ziel der vorliegenden Arbeit war einerseits die Expression von Dkk-1 in Endothelzellen in 
vivo und in vitro zu untersuchen und andererseits die Regulation von Dkk-1 in der 
Endothelzellaktivierung zu betrachten. Ein weiteres Ziel war es die Expression von Dkk-1 unter 
hypoxischen Bedingungen mit der Expression von ß-catenin zu vergleichen, und zu 
untersuchen, ob Dkk-1 einen Einfluß auf proangiogenetische Faktoren wie ß-catenin und VEGF 
haben könnte. 
Die vorliegende Arbeit zeigt, dass Dkk-1 in vitro sowohl in embryonic endothelial progenitor 
cells (eEPCs) als auch in human umbilical vein endothelial cells (HUVECs) exprimiert wird. 
Diese Zellen sind Beispiele für unreife endotheliale Vorläuferzellen und für reife 
Endothelzellen. Es zeigte sich, dass die Dkk-1-Expression sowohl in eEPCs, die mit einem 
Differenzierungsstimulus (RA/cAMP) aktiviert wurden, als auch durch angiogenetische Stimuli 
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(Hypoxie) oder einen endothelialen Wachstumsstimulus (frisches Medium) supprimiert wird. 
Stimulation von HUVECs mit Hypoxie bestätigte die in den eEPCs beobachtete Supression der 
Dkk-1 Expression. Überexpression von Dkk-1 in HUVECs zeigte, dass Dkk-1 die VEGF-
Expression supprimierte während die Expression von ß-catenin nicht beeinflusst wurde.  
In vivo konnte eine Dkk-1 Expression in den großen peripheren Arterien gefunden werden. 
Untersucht wurde die Mausaorta als Beispiel für ein ruhendes, polarisiertes und nicht-
proliferierendes Endothel, in dem sich die Dkk-1 Expression vornehmlich im Endothel 
lokalisieren ließ. In kleineren Gefäßen wie den Hirngefäßen zeigte sich keine Dkk-1 
Expression. Stattdessen war im Mausgehirn eine Expression von Dkk-1 in Neuronen zu 
beobachten. In einem Tiermodell zur Hirnischämie zeigte sich eine verminderte Expression von 
Dkk-1 in Neuronen des Infarktgebietes. 
Die vorliegende Arbeit demonstriert weiter, dass ß-catenin sowohl in eEPCs und HUVECs 
exprimiert wird. In vitro hatte eine Stimulation von HUVECs durch Hypoxie keinen Effekt auf 
die ß-catenin Expression. In vivo konnte eine ß-catenin Expression in den größeren Arterien des 
Herzens (Koronargefäße) und des Gehirns mit einer vornehmlichen Lokalisation in der glatten 
Muskelschicht der Arterien beobachtet werden. Ein Tiermodell zur Hirnischämie zeigte, dass 
sich die ß-catenin Expression von einer dominanten Expression in der Media der Hirngefäße in 
der vom Infarkt nicht betroffenen Hemisphäre zu einer endothelialen Expression in Gefäßen des 
Infarktgrenzgebietes 48 hrs nach MCAO veränderte.   
Wir schließen daraus, dass eine starke Dkk-1 Expression mit dem ruhenden Phänotyp des 
Endothels im Gegensatz zu einer Supprimierung der Dkk-1 Expression im aktivierten Endothel 
assoziiert sein könnte. Beim Erhalt des ruhenden Endothels könnte Dkk-1 mit der Expression 
von VEGF interagieren. Im Tiermodell zur Hirnischämie zeigte sich kein Hinweis auf eine 
Rolle von Dkk-1 in der Neovaskularisation nach Infarkt, da keine Expression von Dkk-1 in 
Gehirngefäßen gefunden werden konnte. Im Gegensatz dazu zeigte ß-catenin eine Expression in 
 82
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Endothelzellen in der Infarktgrenzzone, was möglicherweise eine Rolle von ß- catenin in der 
Neovaskularisation nach einem Hirninfarkt anzeigt. 
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  ABBREVIATIONS 
10. Abbreviations 
µg    microgram 
µl    microlitres 
° C    celcius 
%    percent 
A    adenine 
A    absorption 
APC   adenomatous polyposis coli 
BAECs   bovine aorta endothelial cells 
BBE   bovine brain extract 
BLAST   Basic Local Alignment Search Tool 
BMP   bone morphogenetic protein 
bp    base pair 
BSA   bovine serum albumin 
C    cytosine 
C3H    mouse strain 
Ca2+   Calcium2+
cAMP    cyclic Adenosine-Monophosphate 
CD    cord blood-derived 
cDNA   complementary desoxyribonucleic acid 
CKI   casein kinase I 
CMV   cytomegalie virus 
Cox    cyclooxigenase 
CO2   carbon dioxide  
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  ABBREVIATIONS 
Cy     fluorescence dye, conjugated to secondary antibodies 
DH5α   E. coli bacterial strain 
ddH2O   doubly destilled water 
Dkk/DKK   Dickkopf 
DMEM   Dulbecco´s modified eagle medium 
DMSO   dimethylsufoxide 
DNA   desoxyribonucleic acid 
DNAse   desoxyribonuclease 
dNTP    Deoxyribonucleosidtriphosphate 
Dvl/DVL   Dishevelled 
E. coli   Escherichia coli 
ECs    Endothelial Cells 
EDTA   Ethylendiamintetraacetate 
eEPCs    Embryonic Endothelial Progenitor Cells 
EPCs   endothelial progenitor cell 
et al.   et alii 
ES    embryonic stem cells 
FBS   fetal bovine serum 
FGF   fibroblast growth factor 
Fig.    figure 
FITC    Fluorescein-isothiocyanate (dye conjugated to secondary 
antibodies) 
Flk-1   fetal liver kinase 1 or VEGFR-2 
FrzA (sFRP1)  frizzeled related protein A 
FrzB   frizzled related protein B 
 97
  ABBREVIATIONS 
Fz    frizzled 
G    guanine 
g    gramm 
GA    Gentamicin/AmphotericinB 
GAPDH   glycerinealdehyde-3-phosphate dehydrogenase 
GFAP   glial fibrillary acidic protein 
GSK   glycogen snthetase kinase 
hEGF   human epidermal growth factor 
HEPES    N-(2-Hydroxyethyl)piperazin-N`-2-ethansufloacid 
hFGF   human fibroblast growth factor 
HIF    hypoxia inducible factor 
h/hrs   hour/hours 
HUVECs   human umbilical vein endothelial cells 
IGF    Insulin like growth factor 
IgG    Immunoglobuline G 
IP    isoelectric point 
kb    kilobases 
Krm   Kremen  
l    liter 
LB medium  Luria-Bertani medium 
LDL   low density lipoprotein 
Lef    lymphoid enhancer binding factor 
LRP   lipoprotein-related protein 
MCA   middle cerebral artery 
MCAO   middle cerebral artery occlusion 
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  ABBREVIATIONS 
MCS   multiple cloning site 
M-CSF   macrophage colony stimulating factor 
min    minutes 
ml    millilitres 
mM    millimol 
MMP   matrix metalloproteinase 
mw    molecular weight 
mRNA   messenger ribonucleic acid 
NCBI   National Center for Biotechnological Information 
NeuN   neuron-specific nuclear protein 
ng     nanogram 
NMDA   N-methyl-D-aspartate 
HIH3T3   tumor cell line 
nm    nanometers 
O2    oxygen 
OD    optical density 
O/N    overnight 
PBS    Phosphate buffered saline 
PCP   planar cell polarity 
PCP/CE   Planar cell polarity/Convergent extension 
PCR    Polymerase Chain Reaction 
PECAM    Platelet Endothelial Cell Adhesion Molecule 
PLGF   placental growth factor 
pmol   picomol 
RA    retinoic acid 
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  ABBREVIATIONS 
RNA   ribonucleic acid 
RNAi   ribonucleic acid interference 
RNase    Ribonuclease 
rpm    rounds per minute 
RT    reverse transcriptase 
RT-PCR    Reverse Transcriptase Polymerase Chain Reaction 
sec    seconds  
sFRP   secreted frizzled related protein 
T    thymin 
T17b    murine eEPC line 
Taq Polymerase  polymerase from thermophilus aquaticus 
TBE    Tris-borate EDTA 
Tcf    T-cell-specific transcription factor 
Tris    Tris(hydroxymethyl)-aminomethane 
U    Unit 
UV    ultra violet 
V    Volt 
VE-cadherin  vascular endothelial cadherin 
VEGF    Vascular Endothelial Growth Factor 
VEGFR   vascular endothelial growth factor-receptor 
vWF   von Willebrand factor 
WIF   Wnt inhibitory factor  
Wnt   named after the Drosophila wingless (wg) and the mouse Int-1 genes 
w/v    weight/volume
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